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1 Zusammenfassung
Systematisch verabreichte Chemotherapeutika sind oft uneffektiv bei der Behandlung  von
Krankheiten des zentralen Nervensystems (ZNS). Eine der Ursachen hierfür ist der
unzureichende Arzneistoff-Transport ins Gehirn aufgrund der Blut-Hirn-Schranke, die den
Austausch von Substanzen zwischen  Blutkreislauf und der extrazellularen Flüssigkeit des
Gehirns einschränkt. Die Blut-Hirn-Schranke wird aus Endothelzellen der Hirngefäße
gebildet, die im Gegensatz zu peripheren Endothelien durch die sogenannten „tight
junctions“ verbunden sind. Während diese strukturelle Barriere die Diffusion hydrophiler
Substanzen in die parazelluläre Flüssigkeit des Gehirns verhindert, wird eine Anreicherung
lipophiler Moleküle im Gehirn durch die sehr leistungsfähigen ABC-Efflux-Transporter
wie   zum   Beispiel   P-Glykoprotein   (P-gp)   oder   „Multidrug   Resistance“-Proteine
konterkariert.
Eine   der   Strategien   für   den   nicht-invasiven  Wirkstoff-Transport   ins   Gehirn   ist   die
Verwendung von Nanopartikeln. Wie groß angelegte pharmakologische Studien gezeigt
haben, können Polybutylcyanoacrylat-Nanopartikel, die mit Polysorbat 80 (Tween
®  80)
überzogen wurden, die Blut-Hirn-Schranke passieren und somit  Wirkstoffe ins Gehirn
transportieren.   Es   konnte   gezeigt   werden,   dass   die   Wirkung   der   Polysorbat   80-
Beschichtung nicht mit anderen Tensiden wie Poloxamer 188, 338 und 407 und Poloxamin
908   erreicht   werden   konnte.   Einzig   die   mit   Polysorbat   80   beschichteten
Polybutylcyanoacrylat-Nanopartikel konnten den Transport des Wirkstoffes ins Gehirn
gesunder   Versuchtiere   ermöglichen.  Dieses   Phänomen   wurde   durch   die   selektive
Adsorption bestimmter Plasmaproteine (insbesondere der Apolipoproteine E und B) an die
Oberfläche der Polysorbat 80-beschichteten  Nanopartikel erklärt. Auf diese Art ahmten die
überzogenen   Nanopartikel     Lipoproteinteilchen   nach   und   wurden   durch   Rezeptor-
vermittelte Endozytose über die Blut-Hirn-Schranke transportiert.
Wird die Blut-Hirn-Schranke durch einen Hirntumor partiell beschädigt und hierdurch ihre
Permeabilität am Ort des Tumors erhöht, können Nanopartikel den Tumor zusätzlich durch
den sogenannten EPR-Effekt („Enhanced Permeability and Retention“) erreichen. Es ist
bekannt, dass dieser Effekt besonders ausgeprägt bei lang-zirkulierenden Nanopartikeln ist,
die nicht schnell durch das retikulo-endotheliale System (RES) aus der Blutzirkulation
entfernt werden, was letztlich ihre Extravasation in den Nicht-RES-Geweben erhöht.
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Im ersten Teil der vorliegenden Arbeit wurde die Beladung der Nanopartikel durch
Variation der Formulierungparameter mit dem Ziel optimiert, eine Formulierung mit
höherer Wirksamkeit für die Therapie von Glioblastom-tragenden Ratten zu entwickeln. 
Außerdem wurde das Potential von Doxorubicin, das an mit „Stealth Agents“ überzogenen
Polybutylcyanoacrylat-Nanopartikel   gebunden   war,   für   die   Chemotherapie   von
Hirntumoren untersucht.
Im zweiten Teil dieser Studie wurden die Gehirn- und Körperverteilung in gesunden und in
Glioblastom-101/8-tragenden   Ratten   nach   i.v.-Gabe   von   Poly(butyl-2-cyano[3-  
14C]
acrylat)-Nanopartikeln, die mit Polysorbat 80 beschichtet wurden, und solchen, die noch
zusätzlich  mit Doxorubicin geladen waren (DOX-
14C-PBCA + PS), untersucht.
Anti-tumoraler Effekt von Doxorubicin-beladenen Polybutylcyanoacrylat-
Nanopartikeln im Ratten-Gliom-Modell
Die  Standardformulierung  von Doxubicin-Polybutylcyanoacrylat-Nanopartikeln  (DOX-
NP) wurde durch anionische Polymerisierung von Butylcyanoacrylat in Anwesenheit von
DOX hergestellt.  Zusätzlich wurden unterschiedliche DOX-NP Formulierungen durch
Veränderung   der   Herstellung   produziert.   Diese   veränderten   Parameter   waren:  pH,
Konzentration und Art der Monomere, Konzentration und Art des Stabilisators, sowie
Polymerisationszeit   und   Zugabe   des   Arzneistoffs   am   Anfang   des   Polymerisations
prozesses.   Die   Bestimmung   der   Beladung   wurde   mit   Hilfe   von    HPLC   und
Spektrophotometrie durchgeführt. Außerdem wurde die Verwendung von iso-BCA anstelle
von n-BCA untersucht, und dabei wurden Nanopartikeln mit verbesserter Beladung
erhalten. Die Veränderung der Herstellungparameter führten durch Verkleinerung der n-
BCA-Konzentration (0.75 % w/v), Erhöhung der Dextran-Konzentration (2 % w/v),
Verlängerung der Polymerisationszeit auf 4 h und Zugabe von DOX schon vor dem Start
des Polymerisationsprozesses ebenfalls zu  einer neuer  Formulierung mit verbesserter
Beladung. Das therapeutische Potential der beschriebenen Formulierungen wurde in Ratten
mit   ins   Gehirn   transplantieren   Glioblastom   101/8   untersucht   und   mit   der
Standardformulierung verglichen. Die Applikation allen Präparationen erfolgte durch
intavenöse Injektion in die Schwanzvene. Neben Polysorbat 80 wurden Poloxamer 188 und
Poloxamin 908 als Überzugsmaterial verwendet.  Die Resultate ergaben, dass die mit
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Polysorbat 80 überzogene Standardformulierung am effektivsten war:  35 % der Tiere
überlebten 180 Tage lang nach Tumorimplantation. In den Tiergruppen, die mit iso-PBCA-
Nanopartikeln oder der neuen Formulierung behandelt wurden, lag der Prozentsatz der
Langzeit-Überlebenden bei 15 % (3/20) beziehungsweise 10 % (2/20). Der Prozentsatz der
Langzeit-Überlebenden, die mit Poloxamer 188 oder mit Poloxamin 908 beschichteten
DOX-Nanopartikeln behandelt wurden, lag bei 20 % (4/20).
Die höhere Wirksamkeit von DOX-NP+PS 80 könnte durch die Fähigkeit dieser Träger
erklärt werden, den Wirkstoff während eines frühen Stadiums der Tumorentwicklung
durch einen Rezeptor-vermittelten Mechanismus, der durch den PS 80-Überzug aktiviert
wurde über die intakte Blut-Hirn-Schranke, zu transportieren. Auf diesem Weg könnte
DOX auch jene Teile des Gehirns erreichen, die trotz des Tumors noch immer durch eine
intakte   Blut-Hirn-Schranke   geschützt   wurden.  Unsere   Ergebnisse   zeigen  auch,  dass
Poloxamer 188 und Poloxamin 908 den antitumoralen Effekt von DOX-PBCA beträchtlich
verbessern, obgleich der an die Partikel gebundene Wirkstoff durch das Beschichten mit
diesen Tensiden gemäß früherer Ergebnisse nicht ins gesunde Gehirn transportiert werden
konnte. Der anti-tumorale Effekt dieser Formulierungen könnte möglicherweise dem EPR-
Effekt zugeschrieben werden. Es  ist bekannt, dass die tumorale Arzneistoff-Aufnahme
durch den EPR-Effektes für lang-zirkulierende Wirkstoffträger ausgeprägter ist und so
mehr Wirkstoff durch die Tumor-geschädigte Blut-Hirn-Schranke gelangt. Die Strategie
hierzu,   die   Blut-Halbwertszeit   der   Partikel   zu   erhöhen,   ist   die   Abschirmung   ihrer
Oberfläche. Infolgedessen erfolgt durch das Beschichten mit Tensiden wie Poloxamer 188
und Poloxamin 908 eine Reduktion der Opsonisierung. 
Der Prozentsatz der überlebenden Tiere nach Behandlung mit der neuen Formulierung mit
der erhöhten Beladung war in den vorliegenden Untersuchung nicht besser als die
Standardformulierung. Eine mögliche Erklärung hierfür könnte der erhöhte Dextran-Gehalt
(2 % w/v) sein.  Die Dextran-Moleküle stehen von der Nanopartikel-Oberfläche wie
hydrophile Schleifen oder Ketten ab, so dass sie mit der Polysorbat 80-Schicht interagieren
und  so   die  Partikel-Interaktion  mit   den   Gehirn-Endothelzellen   behindern   könnten.  
Infolgedessen wird der Prozess der Endozytose von den Endothelzellen der Blut-Hirn-
Schranke vermindert, und dementsprechend der Transport von DOX ins Gehirn. Im Falle
von iso-Butyl-NP könnte es möglich sein, dass beide Polymere unterschiedliches Verhalten
in vivo zeigen. Dies genau zu ermitteln würde jedoch weitere Untersuchungen erfordern.
Korpenverteilung von DOX-
14C PBCA-Nanopartikeln in gesunden und Glioblastom
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101/8-tragenden Ratten 
Unbeschichtete   Nanopartikel,   Polysorbat   80-beschichtete   Nanopartikel   oder   mit
Doxorubicin beladene und mit Polysorbat 80 beschichtete Nanopartikel wurden in die
Schwanzvene von gesunden Ratten injiziert. Nach  unterschiedlichen Zeitintervallen (10
Minuten, 1 h, 6 h, 24 h, 1 Woche, 4 Wochen), wurden die Tiere getötet. Blut sowie Leber,
Milz, Lungen, Nieren, Gonaden wurden gesammelt und das Gehirn entfernt.  Nach der
Solubilisierung der Gewebe wurde die  Radioaktivität mittels eines Scintillation gemessen.
Das gleiche Verfahren wurde für Tumor-tragende Ratten verwendet. Die Verabreichung
der Nanopartikel wurde an den Tagen 5, 8 und 10 nach Tumorimpfung durchgeführt und
die Tiere 10 Minuten, 1 h, 6 h, 24 h nach Verabreichung getötet. Das Blut und die Organe
wurden gesammelt und deren Radioaktivität bestimmt. Drei verschiedene Nanopartikel-
Präparationen wurden verwendet: 1. [
14C]-PBCA NP, 2. [
14C]-PBCA NP beschichtet mit
PS 80 und 3. mit DOX-beladene [
14C]-PBCA NP beschichtet mit PS 80. Diese zeigten
einer unterschiedliche Korpenverteilung in den  Ratten. Wie  erwartet, sammelten sich
unbeschichtete Nanopartikel in den RES-Organen wie Lunge, Leber und Milz an. Mit PS
80 beschichtete NP reduzierten die Aufnahme der NP in Leber und Milz, während sich die
Konzentration der NP in der Lunge erhöhte. Diese Beobachtungen deuten darauf hin, dass
die Änderung der Oberflächeneigenschaften der NP durch das Tensid analog zu den
Arbeiten der Arbeitsgruppe Müller, Berlin, zu einer Interaktion mit unterschiedlichen
Opsoninen führt, welches die Aufnahme der NP von verschiedenen phagozitierenden
Zellen erleichtert.
Hingegen war die Aufnahme der mit DOX beladenen, PS 80-beschichteten Nanopartikel
den unbeschichteten Partikel ähnlich. Das Vorhandensein von DOX führte sogar zu einer
geringfügigen Zunahme der RES-Aufnahme und wirkte dem beschichtenden Polysorbat
entgegen.  Die unterschiedlichen Muster der Nanopartikelverteilung können durch ihre
unterschiedlichen physikalisch/chemischen Parameter erklärt werden.  Die Messung des
Zeta-Potentials der in Wasser resuspendierten NP und der in Rattenplasma inkubierten NP
zeigte, dass unbeladene NP negativ geladen waren, während nach DOX-Bindung die
Ladung positiv wurde. Nach der Inkubation im Serum wurde die Ladung der DOX - NP
wieder negativ, was durch eine  starke Interaktion mit Serumbestandteilen bewirkt wurde.
Hieraus kann geschlossen werden, dass die Oberflächenladung, die auf den Nanopartikeln
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vorhanden ist, eine wichtige Rolle in der Proteininteraktion spielt, welche wiederum die
Verteilung im Körper beeinflusst.  
Das Verteilungsmuster von [
14C]-Nanopartikeln in den Körpern von gesunden- und Tumor
tragenden Ratten außerhalb des Gehirns war ähnlich.  Dieses Resultat zeigt, dass der
Gehirntumor nicht die Physiologie des vollständigen Körpers beeinflusst. 
Im Vergleich mit gesunden Ratten und mit Ratten, welche 5 bzw. 8 Tage vorher mit dem
Tumor infiziert wurden, hingegen war die Konzentration der NP im Gehirn von Tumor
tragenden Ratten 10 Tage nach der Tumor-implantation signifikant höher. In Anwesenheit
des Glioblastoms ist der Transport von NP in das Gehirn das Resultat verschiedener
Faktoren: zusätzlich zur Fähigkeit von PS 80-Nanopartikeln, die Blut-Hirn-Schranke zu
passieren, welche in einem frühen Stadium  der Tumorentwicklung noch intakt ist,
extravasieren diese Träger wegen des EPR Effekts über das durch den Tumor undichte
Endothelium. In einigen Teilen des Tumors sind die Kapillaren nämlich hyper-permeabel,
wogegen in anderen Teilen des Tumors ihre Sperrfunktion beibehalten wird. Dadurch wird
die Fähigkeit von PS 80-coated Nanopartikeln Arzneistoffe über die intakten Blut-Hirn-
Schranke zu transportieren aufgrund des „EPR-Effekts“, erhöht. Die Konzentration von PS
80 [
14C]-PBCA NP war im Glioblastom signifikant höher als mit  DOX [
14C]-PBCA NP. 
Dieses Phänomen kann durch die unterschiedliche  Mikroumgebung von zerebralem intra-
tumoralen   und   intaktem   Gehirngewebe   erklärt   werde.   Die   tumorale   Regionen   sind
hypoxisch, ein physiologisches Anzeichen dafür ist die erhöhte Azidose in den betroffenen
Regionen. Diese erhöhte Azidose kann   sich in die nähere Umgebung der tumoralen
Regionen ausdehnen. Hierdurch wiederum kann die Anreicherung der Nanopartikeln
beeinflusst werden. Insbesondere können sich die positive Ladung der tumoralen Regionen
und die positive Ladung der DOX [
14C]-PBCA NP negativ beeinflussen. Dennoch waren
die Doxorubicin-Konzentration in Glioblastom ausreichend, einen therapeutischen Effekt
zu ermöglichen.
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2 Introduction
2. 1 Glioblastoma multiforme
2.1.1 Background
Brain   tumours   represent   a   heterogeneous   group   of   central   nervous   system   (CNS)
neoplasms.   The   World   Health   Organization   (WHO)   recognizes   approximately   100
different types of brain tumours classified according to pathological diagnosis. In general,
however, these tumours can be classified into either primary or secondary tumours,
depending on whether they originate in the brain or simply spread to the central nervous
system from elsewhere. Approximately half of all primary brain tumours are glial-cell
neoplasms,   and   more   than   three   quarters   of   all   glial   tumours   are   astrocytomas.
Astrocytomas differ in their pathological and clinical behaviour: some astrocytomas are
classified as low-grade tumours, meaning they are slow growing, whereas others, such as
glioblastoma multiforme (GBM), represent the most aggressive type of tumour known to
occur within the CNS (Fig 2.1).
Figure 2.1. Development and progression of astrocytic brain tumours. Malignant brain tumours can arise in
one of two ways. On the one hand, astrocytes undergo genetic changes accompanied by upregulation of
certain receptors, such as the platelet-derived growth factor (PDGF), endothelial growth factor receptor
(EGFR) or vascular endothelial growth factor (VEGF). These progressive changes culminate in the formation
of a glioblastoma. On the other hand, most primary glioblastomas arise de novo, without the need for gradual
progression from an astrocytoma to a high-grade astrocytoma to a glioblastoma multiforme.
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2.1.2 Pathophysiology
Over the past 5 years, the concept of different genetic pathways leading to the common
phenotypic endpoint (i.e., GBM) has gained general acceptance. Genetically, primary and
secondary glioblastomas show little overlap and constitute different disease entities. Some
of the more common genetic abnormalities are described as follows (Fig 2.1): 
p53: Mutations in p53, a tumour suppressor gene, were among the first genetic alterations
identified in astrocytic brain tumours. While present in less than 10 % of primary
glioblastomas, more than 65 % of secondary glioblastomas have p53 mutations. 
Epidermal growth factor receptor (EGFR) gene: The EGFR gene is involved in the control
of cell proliferation and is either amplified or overexpressed in more than one third of
glioblastomas, sometimes in a truncated and rearranged form. EGFR amplification is much
more common in primary glioblastomas. These tumours typically show a simultaneous loss
of chromosome 10 but rarely a concurrent p53 mutation. 
MDM2: Amplification or overexpression of MDM2 constitutes an alternative mechanism
to escape from p53-regulated control of cell growth by binding to p53 and abolishing its
activity. Overexpression of MDM2 is observed in more than 50 % of primary GBMs but
rarely in secondary glioblastomas. 
Platelet-derived growth factor (PDGF) gene: The PDGF gene acts as a major mitogen for
glial cells by binding to the PDGF receptor (PDGFR). Amplification or overexpression of
PDGFR is typical (60%) in the pathway leading to secondary glioblastomas. 
PTEN: PTEN (also known as MMAC and TEP1) encodes a tyrosine phosphatase located at
10q23.3. The function of  PTEN  as a cellular phosphatase is consistent with possible
tumour suppressor function. Phosphatases act by turning off signaling pathways dependent
upon phosphorylation. When phosphatase activity is lost because of genetic mutation,
signaling pathways can become activated constitutively, resulting in aberrant proliferation.
PTEN mutations have been found in as many as 30 % of glioblastomas. 
2.1.3 Treatment strategies for brain gliomas
Current treatments for malignant or high-grade gliomas rarely achieve long-term tumour
control.   Even   when   treated   with   aggressive   combined   surgery,   chemotherapy,   and
radiotherapy, in patients with high-grade malignant brain gliomas such as glioblastomas,
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recurrence occurs between 6 and 12 months and for anaplastic astrocytomas, within 18–36
months. 
Conventional therapy for glioblastomas consists primarily of surgical debulking followed
by radiation therapy. However glioblastoma tumours can be difficult to resect due to the
lack of a defined tumour edge; the tumour may extend onto normal-looking brain tissue,
and/or can be localized near critical areas of the brain. The median survival after surgical
intervention is six months (Shand et al. 1999).
Following surgery to remove as much tumour mass as possible or if the tumour is in a non-
operable region of the brain, radiation treatment can be performed to kill residual tumour
cells and to relieve symptoms associated with the disease. Exposure of radiation is
confined to the tumour mass and 2 cm of surrounding tissue. As with all radiation
treatments, the side effects include swelling of the brain and the accumulation of dead
cells, making it difficult to assess tumour reduction during routine scans.
The use of chemotherapy is now well established in the treatment of brain tumours. As is
also the case with many systemic cancers, chemotherapy of brain tumours is not curative,
and the goals of the treatment are mainly to control the growth of the tumour and to
maintain good performance and quality of life for the patient for as long as possible
(Burton and Prados 2000, Beauchesne 2002; Kleinberg et al. 2002; Tentori and Graziani
2002, Trent et al. 2002, Watling  and Cairncross 2002). Chemotherapy can be used as a
primary therapy or an additional therapy following surgery and/or radiation therapy. The
most   common   agents   are   the   nitrosoureas   (BCNU,   CCNU),   platinum-based   drugs
(cisplatin, cisplatinum, carboplatin), temozolomide, procarbazine, and natural-occurring
compounds (taxol). The failure of aggressive chemotherapy to eradicate brain tumour is
due in part to the presence of the blood-brain barrier (BBB) which restricts the influx of
molecules from the bloodstream into the brain and prevent the effective therapy of brain
tumour (Hofer and Merlo 2002). Compounds which temporary disrupt the BBB can
increase the penetration of drug into the brain parenchyma. Certain hyperosmolar agents,
such mannitol, draw water out of endothelial cells, thereby shrinking them and opening the
gaps between cerebral endothelial cells. Other compound, such as  the bradykinin agonist
RMP-7, directly distrupt the BBB (Bonstelle et al. 1983, Nomura et al. 1994). However,
the enhanced toxicity associated with the disruption of the BBB limits the applicability of
these methods.
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2.2 Blood-brain barrier
2.2.1 Structure of the Blood-Brain Barrier
The brain functions within a well-controlled environment separate from the milieu of the
periphery.   The   mechanisms   that   control   the   unique   environment   of   the   brain   are
collectively referred to as the blood-brain barrier.
 Paul Ehrlich (1885, 1906) and Edwin Goldman (1909, 1913) observed that water soluble
dyes  injected   into   the   peripheral   circulation   did   not   stain   the   brain  or   color   the
cerebrospinal   fluid   (CSF).   Lewandowsky,   while   studying   potassium   ferrocyannide
penetration into the brain (1900), was the first to coin the term blood-brain barrier and
called it "Blut-Hirn-Schranke". The observations drawn from the dye studies brought about
the concept of a barrier between blood and brain, as well as between blood and CSF.
Electron microscopic cytochemical studies performed in the late 1960s by Reese and
Karnovsky (1967), and later by Brightman and colleagues (1969) visualized the BBB.
 The BBB is the specialized system of capillary endothelial cells that protects the brain
from harmful substances in the blood stream, while supplying the brain with the required
nutrients for proper function.  Unlike peripheral capillaries that allow relatively free
exchange of substance across / between cells, the BBB strictly limits transport into the
brain through both physical (tight junctions) and metabolic (enzymes) barriers. Thus the
BBB is often the rate-limiting factor in determining permeation of therapeutic drugs into
the brain.
The structure of the BBB is schematised in Fig 2.2. The cerebral endothelial cells form
tight junctions at their margins where they meet, which completely seal the aqueous
paracellular pathways between the cells. Pericytes are distributed discontinuously along the
length of the cerebral capillaries and partially surround the endothelium. Both, the cerebral
endothelial cells and the pericytes are surrounded by, and contribute to, the same
extracellular matrix. Foot processes from astrocytes form a network fully surrounding the
capillaries. Axons from neurons also abut closely against the endothelial cells and contain
vasoactive neurotransmitters and peptides. Microglia (perivascular macrophages) are the
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resident immunocompetent cells of the brain and are derived from systemic circulating
monocytes and macrophages. 
 Figure 2.2. Schematic diagram of the neurovascular unit/cell association forming the BBB. 
 
2.2.2 Anatomy and physiology of the cerebral capillary endothelia 
The surface area of the brain microvasculature is ~ 100 cm
 2·g
-1 tissue, with the capillary
volume and endothelial cell volume constituting approximately 1 % and 0.1 % of the tissue
volume, respectively (Pardridge et al. 1990). The mean intercapillary distance in the human
brain is ~ 40 mm (Duvernoy et al. 1983). This short distance allows for near instantaneous
solute equilibration throughout the brain interstitial space for small molecules, once the
BBB has been overcome. The microvasculature of the central nervous system (CNS) can
be   differentiated   from   the   peripheral   tissue   endothelia   in   that   it   possess   uniquely
distinguishing characteristics:
a) Cerebral capillary endothelial cells contain  tight junctions, which seal cell-to-cell
contacts between adjacent endothelial cells forming a continuous blood vessel. The tight
junctions between BBB endothelial cells lead to a high endothelial electrical resistance, in
the range of 1500-2000 Ω × cm
2 (pial vessels), as compared to 3-33 Ω × cm
2 in other tissues
(Crone and Christensen 1981; Butt et al. 1990). The electrical resistance across in vivo
cerebral microvessel endothelial cells, of non-pial origin, has been estimated to be as high
as 8000 cm
2 (Smith and Rapoport 1986). The net result of this elevated resistance is low
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paracellular permeability.
The endothelial and epithelial tight junction consists of three integral membrane proteins:
claudins, occludin, and a junctional adhesion molecule (JAM) which, together with several
peripheral proteins, constitute the junctional complex (Fig 2.3). A number of peripheral
proteins, regarded as scaffolding or linkers for the integral molecules of the tight junction
in endothelia and epithelia, form a cytoplasmic plaque adjacent to the junctional cell
membrane. The plaque proteins are part of the tight junction complex and include the
guanylate kinases: ZO-1 (220 kDa), ZO-2 (160 kDa) and ZO-3 (130 kDa). Another plaque
protein is cingulin (140 kDa), which is myosin-like and binds to the ZO complex and to F-
actin of the cytoskeleton (Cordonesi et al. 1999).
Figure 2.3. Schematic representation of tight junctions
 b) The cytoplasm of the endothelial cell is of uniform thickness, with very few pinocytotic
vesicles (hollowed out portion of cell membrane filled with fluid, forming a vacuole which
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allows for nutrient transport), and lack fenestrations (i.e. openings). Therefore, transit
across the BBB involves translocation through the capillary endothelium, the internal
cytoplasmic domain,  and then through the ablumenal membrane and pericyte and / or
basal lamina. Three principle types of transendothelial transport have been postulated.
c) There is a  greater number and volume of mitochondria  in BBB endothelial cells
compared to peripheral endothelia in rat (Odendorf et al.  1977). This increase in
mitochondria, and increased energy potential is thought to be required for active transport
of nutrients to the brain from the blood. Oldendorf and Brown (1975) estimated that 5 - 6
times more mitochondria per capillary cross-section exist in rat cerebral capillaries than in
rat skeletal muscle capillaries. These finding suggest that the enhanced cerebral capillary
work capacity may be related to energy-dependent transcapillary transport.
d) There is also an enzymatic barrier at the cerebral endothelia, capable of metabolizing
drug and nutrients (Brownlees et al. 1993; Brownson et al. 1994). These enzymes are
principally directed at metabolizing neuroactive blood-borne solutes. Enzymes such as g-
glutamyl transpeptidase (g-GTP), alkaline phosphatase, and aromatic acid decarboxylase
are in elevated concentrations in cerebral microvessels, yet often in low concentrations or
absent in non-neuronal capillaries. 
e) A  polarity exists between the lumenal and ablumenal membrane surfaces  of the
endothelial cells. The concept of the functional polarity of the BBB emerged from
quantitative biochemical studies (Betz and Goldstein 1978). The enzymes  g-GTP and
alkaline phosphatase are shown to be present at the lumenal endothelium, whereas Na
+-K
+-
ATPase   and   the   sodium   dependent   (A-system)   neutral   amino   acid   transporter   are
associated with the ablumenal portion of the endothelium (Betz et al. 1980). The glucose
receptor   GLUT-1   was   shown,   through   use   of   immunogold   labeling   and   electron
microscopy, to have a 3 : 1 ratio of distribution, ablumenal to lumenal at the BBB (Farrell
and Pardridge, 1991). Na
+-K
+-ATPase is enriched at the ablumenal surface (Betz et al.
1980). Additionally, the P-glycoprotein (P-gp) drug efflux transporter is presently thought
to exist at the lumenal membrane surface, although arguments that P-gp is actually
associated with the astrocytes which enfold the endothelial cells (Pardridge 1997) is
presently  being  debated.   Structural,   pharmacological,   and   biochemical   evidence  for
lumenal and ablumenal polarization of receptors, enzymes, and channels at the cerebral
endothelia (Vorbrodt 1993) establishes the BBB to be a working non-stagnant membrane
unequivocally evolved to maintain brain homeostasis.
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2.2.3 Transport at the blood-brain barrier  
2.2.3.1 Cell migration
The barrier endothelium that restricts polar solutes from entering normal brain also
restrains circulating immunocytes. Activated cells, nevertheless, can penetrate the brain. T-
lymphocytes, stimulated non-specifically, in vitro, with the mitogenic lectin, concanavalin-
A and re-injected into blood, enter CNS randomly then leave. T cells not only enter the
CNS but are retained within it only after they are presented with and recognize brain-
specific antigens (Hickey 1999) (Fig 2.4 a). Passage across endothelium must be preceded
by temporary adhesion of the lymphocytes to the endothelium by way of cell adhesion
molecules expressed on both immunocytes and endothelium. Immunocytes migrate across
CNS endothelium both paracellularly and transcellularly.
2.2.3.2 Passive diffusion
The passive diffusion proceeds from low to high concentrations. Simple diffusion is a
spontaneous process depending on random movement of solutes. The free-energy change
of a solute diffusing across a membrane is directly dependent on the magnitude of the
concentration gradient (Fig 2.4 b).
2.2.3.3 Carrier-mediated efflux 
 The carrier-mediated efflux is involved in extruding drugs from the brain and is a major
obstacle   for   many  pharmacological   agents,   with   the   ABC   (ATP   binding   cassette)
transporter P-glycoprotein being the principle efflux mechanism of these agents (Cordon-
Cardo et al. 1989) (Fig 2.4 c). There also exists efflux transporters for organic anions, via
multidrug resistance associated protein (MRP) (Kusuhara et al. 1998), and anionic and
cationic cyclic peptide (Tsuji 2000). 
2.2.3.4 Facilitated diffusion 
Facilitated diffusion is a form of carrier-mediated endocytosis, in which solute molecules
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bind to specific membrane protein carriers, also from low to high concentration. The
binding of a solute to a transporter on one side of the membrane triggers a conformational
change in the protein; this results in a carrying through of the substance to the other side of
the membrane, from high to low concentration. Facilitated diffusion is passive (i.e. energy
independent)   and   contributes   to   transport   at   the   BBB   of   substances   such   as
monocarboxyates, hexoses amines, amino acids, nucleoside, glutathione, small peptide, etc.
(Tamai and Tsuji 2000) (Fig 2.4 d).
2.2.3.5 Vesicular transport
Although certain ions and solutes are selectively transferred across CNS endothelium by
special carriers, some solutes and viruses are transported across cells by vesicular
transcytosis. Transcytosis begins as a microinvagination of the cell membrane to form a pit
or caveola. The pit pinches off as a free vesicle that migrates across the cell to the opposite
cell membrane to which it fuses and releases its contents into the periendothelial basal
lamina. What little solute is incorporated by fluid-phase endocytosis in brain endothelium
is usually destined for enzymatic degradation in cytoplasmic organelles such as lysosomes.
2.2.3.5.1 Receptor-mediated transcytosis (RMT) 
This process provides a means for selective uptake of macromolecules. Cells have
receptors for the uptake of many different types of ligands, including hormones, growth
factors, enzymes, and plasma proteins. RMT occurs at the brain for substances, such as
transferrin (Morgan and Moos 2002), insulin (Duffy and Pardridge 1987), leptin (Banks et
al. 1996), and IGF-I & IGF-II (Duffy et al. 1988), and is a highly specific type of energy
dependent transport (Fig 2.4 f).
2.2.3.5.2 Absorptive-mediated trancytosis (AMT) 
AMT is triggered by an electrostatic interaction between a positively charged substance,
usually a charge moiety of a peptide, the negatively charge plasma membrane surface (i.e.
glycocalyx) (Gonatas et al. 1984). AMT has a lower affinity and higher capacity than
receptor-mediated endocytosis. The development of many new drug delivery technologies
focuses on AMT (Pardridge 1999).
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2.2.3.6 Tight junction modulation
The phosporylation of the proteins constituting tight junctions enhances their permeability,
as assesed in vitro, by the passive flux or extracellular probes such albumin or inulin.
Moreover extracellular signals can influence the permeability of the tight junction by the
cytoskeleton (Begley and Brightman 2003) (Fig 2.4 g).
Figure 2.4. Potential routes for transport across the BBB. (a) Leukocytes may cross the BBB adjacent to, or
by modifying, the tight junctions. (b) Solutes may passively diffuse through the cell membrane and cross the
endothelium. Greater lipid solubility favors this process. (c) Active efflux carriers may intercept some of
these passively penetrating solutes and pump them out of the endothelial cell. (d) Carrier-mediated influx,
which may be passive or secondarily active, can transport many essential polar molecules such as glucose,
amino acids, and nucleosides into the CNS. (e) RMT can transport macromolecules such as peptides and
proteins across the cerebral endothelium. (f ) AMT appears to be induced nonspecifically by negatively
charged macromolecules and can also result in transport across the BBB. (g) Tight junctions may be
modulated to allow an increased movement of polar solutes through the aqueus paracellular pathway. 
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2.3 Drug targeting
2.3.1 Background 
The efficacy of many drugs is often limited by the difficulty to reach the site of action. In
most cases, only a small amount of the administered dose of the drug reaches the site,
while the rest of the drug is distributed to the rest of the body depending on its chemical-
physical properties. A site-specific delivery would not only increase the amount of the drug
reaching the site but also decrease the amount being distributed to other parts of the body,
thus reducing unwanted site effect. Site-specific or targeted delivery, therefore,  would also
enable a reduction in the dose to be administrated. By decreasing side effects, it would also
increase the therapeutic index of the drug.
A more specific accumulation at the target site may be achieved by altering the chemical
structure yielding more suitable physicochemical and biochemical properties of the drug.
This strategy involves the synthesis of either a totally new compound or a so-called
prodrug from which the active drug is produced by the body’s own metabolism. Although
these approaches may be very successful in some cases, in others the synthesis of a more
site-specific drug is not possible. For this reason, delivery of the original drug by specially
designed drug delivery systems is the better solution.
A large number of drug delivery systems have been conceived and developed. Among
these systems, colloidal drug delivery systems hold great promise for reaching the goal of
drug targeting.
2.3.2 Strategies for drug targeting
The first idea of drug targeting was originally formulated by Paul Ehrlich in the nineteenth
century. After visiting the opera Der Freischütz by Carl Maria von Weber, in which so
called Freikugeln played a major role, Ehrlich came upon the idea of Zauberkugel - magic
bullets (Kreuter 1992). The Freikugeln in the opera could be fired in any direction yet still
reach their goal. Ehrlich imagined that similar targeted tiny drug-loaded magic bullet
would significantly improve therapy. 
In this model, the magic bullet is composed of two parts: drug and carrier (Fig 2.5). The
targeting of the drug is achieved by a carrier that has a specific affinity to certain organs,
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tissue, or cell. 
Gregoriadis worked on the association between effective and tissue - unspecific drugs, and
inactive and tissue - specific carrier systems (Gregoriadis 1977).
Afterwards Poste (Poste et al. 1984) and Davis (Davis and Illum 1986) differenced the
concept of Drug Targeting  into passive and active targeting.
Passive targeting is defined as a method whereby the physical and chemical properties of
carrier systems increase the target/nontarget ratio of the quantity of drug delivered by
adjusting these properties to the physiological and the histological characteristics of the
target and non - target tissues, organs, and cells. Influential characteristics of passive
targeting are chemical factors such as hydrophilicity/hydrophobicity and positive/negative
charge and physical factors such as size and mass. 
Figure 2.5. Concept of the magic bullet
The active targeting refers to efforts to increase the delivery of drugs to a target through the
use of specific interactions at target sites where a drug’s pharmacological activities are
required.
The active targeting was classified from Widder (Widder et al. 1979) and Kreuter (Kreuter
1985) in:
Targeting 1. order -     Achievement of the capillary - bed of target organs
Targeting 2. order -     Accumulation in the cells of target organs
Targeting 3. order -     Accumulation in determined cellular - systems  of target organs 
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2.3.3 Drug targeting applies to tumour 
The ideal therapeutic system should attack only the tumour and  should be not toxic for the
healthy tissues. Colloidal systems possess the tendency to reach some type of tumour after
intravenous injection (Matsumura and Maeda 1986).
This behaviour makes the colloidal systems a suitable carrier for cytostatic drugs. The
reason of this behaviour is not fully explained so far, but it is indisputable that the increase
of the tissue permeability and the adherence of particles to the tissues play a relevant role
(Luo and Prestwich 2002; McDonald and Baluk 2002). 
Furthermore, the growth of the tumour is associated to a inflammatory reactions, and this
phenomenon leads to the enhanced endocytosis by endothelial cells, to the fenestration of
endothelium, and to the migration of T-lymphocytes to the enflamed tissues (Mahaley
1968; Giometto et al. 1996; Tran et al. 1998). 
The first colloidal systems applied for drug targeting were liposomes. A branch concerning
the application of nanoparticles was developed from the liposome studies. 
Sugibayashi employed nanoparticles for the cure of tumour in animals (Sugibayashi et al.
1979). He used 5-fluorouracil loaded albumin-nanoparticles for the treatment of Ehrlich-
ascites-tumour. The nanoparticles loaded with 5-Fluorouracil showed a higher therapeutic
effect  in comparison to the free drug.
Kreuter used equally 5-fluorouracil bound to poly(butyl cyanoacrylate) nanoparticles as a
carrier system (Kreuter and Hartmann 1983). The tumour investigated was a Crocker –
Sarcoma - S 180. An increase of antitumoural activity of the drug but also toxic effects
(leucopoenia, lose of weight, death of some animals) were observed.
Brasseur (Brasseur et al. 1980) employed PMMA, PHCA and PIBCA as nanoparticle
material for the drug delivery. Again a higher therapeutic effect of the cytostatic drug used
- dactinomycyn - was observed, whereas side effects were reduced overall.     
Doxorubicin is one of the most important anthracyclines in oncology. However, this drug
induces several dose limiting side effects as such cardiac miopathy, alopecia, etc. Couvreur
(Couvreur et al. 1986) showed that the toxicity of doxorubicin bound to nanoparticles was
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decreased, but this preparation was effective only for a  form of  leukaemia.
                     
Further studies were carried out with the purpose to enlarge the therapeutic range of
doxorubicin   nanoparticles.   Kattan   (Kattan   et   al.   1992)   investigated   the   effect   of
doxorubicin loaded PHICA particles on healthy men. He researched the tolerance of this
preparation on healthy men, during the phase I of clinical trials.  No cardiac toxicity was
observed for 85 % of the volunteers. Fever was observed for some individuals and allergy
reactions appeared only in one volunteer. The tolerated dose of doxorubicin nanoparticles
preparations  was established at 75 mg/m
2 at the conclusion of the study.
Further studies used PBCA nanoparticles coated with poloxamer as carrier system (Beck et
al. 1993), and mitoxantrone was applied as the cytostatic drug. 
2.3.4 Enhanced permeability and retention effect (EPR effect)
Differences in the structure and behavior of normal and tumour tissue could be used for
designing drug delivery systems facilitating tumour-specific delivery of the drug or prodrug
and specific drug activation. Generally, three locations in the tumour tissue are used as
targets for delivery of anti-cancer drugs in drug delivery research: tumour vasculature,
extracellular space in the tumour tissue, and tumour cells.
In principle, accumulation of polymer-based drugs in many tumours can be achieved by a
nonspecific or by a specific targeting process. Tumour vasculature continuously undergoes
angiogenesis to provide blood supply that feeds the growing tumour (Hanahan and
Folkman   1996).   High-molecular-weight   (HMW)   molecules   and   nano-sized   particles
accumulate in solid tumours at much higher concentrations than in normal tissues or organs
due to the enhanced permeability and retention (EPR) effect (Maeda 2001; Seymour et al.
1995; Maeda et al. 2000, 2003). In this case, a leaky vasculature and limited lymphatic
drainage, typical of tumour and missing in normal tissue, result in the accumulation of
macromolecules, e.g. macromolecular drug carrier systems in the interstitial space of a
large variety of tumours (Maeda 2001; Maeda et al 1992, 2001) (Fig 2.6). These systems
can release cytotoxic drugs into the extracellular fluid of the tumour tissue (Christie and
Grainger 2003; Takakura and Hashida 1995), or they can release a drug after entering the
- 19 -Introduction
umor cells via fluid-phase, adsorptive or receptor-mediated pinocytosis (Alberts et al
2002). 
Figure  2.6.  Schematic  illustration  of  the EPR effect  principle.  Angiogenesis and enhanced vascular
permeability of tumour capillaries and impaired or missing lymphatic clearance of macromolecules result in
accumulation of macromolecules (polymers) in tumour tissue.
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2.4 Nanoparticles 
2.4.1 Background
Nanoparticles are solid colloidal particles ranging in size from 10 nm to 1000 nm (1 mm).
They  consist   of   macromolecular   materials   in   which   the   active   principle   (drug   or
biologically active material) is dissolved, entrapped, or encapsulated, and/or to which the
active principle is adsorbed or attached (Kreuter 1983). This definition includes not only
particles with structures as described by Birrenbach and Speiser (1976) by the term
“nanopellets” but also “nanocapsules” with a schell-like wall as well as “microspheres”, if
they are below 1mm in size (Kramer 1974; Widder et al. 1970; Kaufmann et al. 1979; Gallo
et al. 1984). It also includes polymer lattices such the “molecular scale drug entrapment”
products by Banker et al. (Goodman and Banker 1970; Larson and Banker 1976).
2.4.2 Nanoparticles as delivery system for CNS-targeting
The central nervous system (CNS) represents one of the most important human organ.
Drugs penetrate hardly into this organ, and the chances to cure disease associated to the
CNS are very limited. The cure of cerebral illness with nanoparticles was conceived
relative early (Kabanov et al. 1989).    
Tröster and Kreuter (1992) investigated the body distribution with labelled PMMA
nanoparticles coated with different surfactants. They found out that the higher value of
radioactivity in the CNS was associated with nanoparticles coated with polysorbate 80.
Tröster explained this phenomenon by the adsorption on nanoparticles to the endothelial
cells of cerebral capillaries.
Bochard demonstrated later, by in vitro studies, that bovine capillaries could take up
nanoparticles coated with surfactants. He could assert that the velocity of nanoparticles
uptake depends on the type of surfactant and on its quantity and the uptake occurred
preferably  for polysorbate 80-coated nanoparticles (Bochard and Kreuter 1993). Bochard
attributed this phenomenon to a membrane permeabilization effect due to surfactants.  
Kreuter and Alyautdin (Kreuter et al. 1995; Alyautdin et al. 1997) investigated the
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transport of a drug into the CNS by PBCA particles in vivo. For this purpose, they used  the
opiate –receptor-agonist hexapeptide dalargin. This drug is not able to cross the BBB after
intravenous injection.  The high dose of 20 mg/Kg of dalargin has no effects (Kalenikova
et   al.   1988).   After   drug   binding   to   nanoparticles   coated   with   polysorbate   80   a
antinociceptive effect   was observed after intravenous injection. The effects appeared
rapidly and reached the maximun after 45 minutes. The results were confirmed later by
Schöder (Schröder and Sabel 1996).
Alyautdin repeated the experiments with nanoparticles bound to loperamide (Alyautdin et
al. 1997). As dalargin, loperamide is not able to cross the BBB. The study showed that
loperamide-nanoparticles coated with polysorbate 80 could reach the CNS. The maximal
possible effect was observed at 15 min post injection. Tubocurarin was used in other
studies (Alyautdin et al. 1998).  
     
2.4.3 Mechanism of nanoparticles-mediated  drug transport to the brain
A number of possibilities exist that could explain the mechanism of the delivery of
substances across the BBB: 
a) An increased retention of the nanoparticles in the brain blood capillaries combined with
an adsorption to the capillary walls. This could create a higher concentration gradient
that would enhance the transport across the endothelial cell layer and as a result the
delivery to the brain. 
b) A general surfactant effect characterized by a solubilization of the endothelial cell
membrane lipids that would lead to membrane fluidization and an enhanced drug
permeability through the BBB. 
c) The nanoparticles could lead to an opening of the tight junctions between the
endothelial cells. The drug could then permeate through the tight junctions in free form
or together with the nanoparticles in bound form. 
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d) The nanoparticles may be endocytosed by the endothelial cells followed by the release
of the drugs within these cells and delivery to the brain. 
e) The nanoparticles with bound drugs could be transcytosed through the endothelial cell
layer. 
f) The polysorbate 80 used as the coating agent could inhibit the efflux system, especially
P-glycoprotein (Pgp).
All these mechanisms also could work in combinations
At present the most likely mechanism of nanoparticle - mediated transport of drugs to the
brain is the mechanism of endocytosis of the nanoparticles and release of the drug in these
cells. Lück (1997) observed an adsorption of apolipoprotein E (apo E) on the surface of
polysorbate 20, 40, 60 or 80-coated nanoparticles after incubation for 5 min in human
citrate-stabilized plasma at 37° C. Only after polysorbate 20, 40, 60, or 80 overcoating an
apo E adsorption was detected.
 These results corroborate the in vivo findings where only polysorbate 20, 40, 60, or 80
induced an antinociceptive effect with dalargin nanoparticles whereas the other surfactants
including those of the in vitro plasma incubation study were unable to induce a significant
effect. The antinociceptive effect of the dalargin nanoparticles was significantly lower if
the nanoparticles were incubated in apo E alone without polysorbate prior to injection, but
it remained similar to coating with polysorbate 80 alone if the particles were coated with
the polysorbate before the incubation with apo E (Alyautdin et al. 1997).
These results are a strong indication that apo E is involved in the nanoparticle-mediated
drug transport to the brain.
Lipoproteins are of critical importance for the delivery of essential lipids to this organ. The
presence of an LDL receptor in the BBB has been demonstrated by a number of authors
(Dehouck et al. 1994, 1997; Méresse et al. 1989; De Vries et al. 1993; Lucarelli er al. 1997;
Cecchelli et al. 1997), and apo E and apo A-I containing particles have been detected in
human cerebrospinal fluid (Pitas et al. 1997). It is very possible that the polysorbate-coated
nanoparticles mimic LDL-particles after apo E adsorption following injection into the
blood. In this way they could act as Trojan horses by interacting with the LDL receptor
leading to their uptake by endocytic processes. Hence, the role of polysorbates would be
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that of an anchor for apo E.
2.4.4 Poly alkyl(butyl cyanoacrylate) nanoparticles 
Poly alkyl(butyl cyanoacrylate) nanoparticles are generally
  prepared from butyl cyano
acrylate monomers (Fig 2.6 a) by emulsion anionic polymerisation (Fig 2.6 b) in an acidic
aqueous
  solution of a colloidal stabilizer such as dextran 70 000, polysorbates,
  and
poloxamers. The polymerization is initiated by the hydroxyl ions of water, and elongation
of the polymer chains occurs by an anionic polymerization mechanism. It should be
pointed out that the anionic polymerization of such a reactive monomer can be controlled
in an aqueous medium. The main parameters involved are the adjustment of the pH with a
strong acid such as hydrochloric acid and the concentration of the anionic polymerization
inhibitor (SO2) in the monomer (Lescure et al. 1992). Inclusion of drug can be made during
the polymerization
 process or by adsorption onto preformed nanoparticles. The length of
the alkyl pendant governs degradation rates (Müller et al. 1990, 1992)
 and toxicity (Lherm
et al. 1992; Kante et al. 1982) of poly(alkyl cyanoacrylate) nanoparticles,
 which decrease in
the order methyl> ethyl> butyl/isobutyl> hexyl/isohexyl.
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Figure 2.6. Chemical structure of alkylcyanoacrylates (A) and scheme of their anionic and zwitterionic
polymerization (B).
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2.5 Body distribution of nanoparticles after intravenous injection
2.5.1 Reticuloendothelial system uptake
After intravenous injection, nanoparticles, like other colloidal carriers, are taken up by the
reticuloendothelial system (RES). The intravenously injected colloids mainly distribute
into the RES organs liver (60-90 % of the injected dose), spleen (2-10 %), lungs (3-20 %)
and a low amount (>1 %) into the bone marrow (Kreuter 1983b, 1985). It has been
acknowledged for over a decade (Kreuter 1983c, Singer 1969) that coating of the injected
colloid particulates with serum components - opsonins - precedes the uptake by the RES
and   that   opsonization   process   strongly  facilitates   or   even   is   necessary   to   induce
phagocytosis of the particles (Van Oss et al. 1975, 1978, 1984; Borchard and Kreuter
1993). 
The surface properties of the particles seems to influence strongly the spectrum of the
adsorbed serum components (Blunk et al. 1991). 
The adsorption of the serum components, mainly proteins, is competitive (Kim et al. 1974)
and is found to be only partially reversible or even irreversible (Soderquist and Walton
1980).   Soderquist   and   Walton   supposed   that   the   hydrophobic   bounding   was   the
predominant force in the adhesion of the protein to foreign surfaces. These hydrophobic
interactions seem to occur due to the unfolding of the proteins that reveals the hydrophobic
interior. This process optimizes hydrophobic interactions and increases the entropy of the
adsorbed material.
The opsonins coat around the injected particulates then seems to trigger their uptake by
cells of the RES (Van Oss et al. 1975, 1984; Van Oss 1978).
2.5.2 Modification of body distribution by coating with surfactants
Based on the above assumption that opsonin adsorption determines the body distribution of
nanoparticles, it can be speculated that different surface properties of the particles will lead
to a different spectrum as well as to different quantities of adsorbed serum component
(Wilkins   1967a).   It  can   further   speculated  that   different   types  of   adsorbed  serum
components will prevent or trigger the uptake of different cells of the RES. Following
along these lines it was early suggested to design or artificially alter the surface properties
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of the particles in order to alter and later to be able to monitor their body distribution
(Kreuter 1983b; Wilkins 1967a, b).
Illum et al. (1983, 1984, 1986a, 1987), Leu et al. (1984), and Tröster et al. (1988, 1990,
1992a, b) used surfactants and polymers to coat nanoparticles in order to modify their body
distribution. All authors could show that surfactants coated onto the surface of the particles
reduce the nanoparticle liver uptake and simultaneously increase their blood serum
concentration.
In their study, Tröster et al. (1990, 1992a, b) investigated 13 surfactants as coating
materials for 
14C-labelled nanoparticles and examined  the radioactivity in organs and tissue
at different time points after intravenous injection to rats. Among these surfactants two lead
substances were identified by the work of Tröster et al., poloxamine 1508 and polysorbate
80. Poloxamine 1508 reduces lever uptake and keeps the particles in the blood circulation.
Since this material in not available any more, poloxamine 908 may be used. Polysorbate 80
was overall the optimal material for increasing nanoparticles concentration in non - RES
organs (Tröster et al. 1990).     
2.5.3 Mechanism of the reduction of the RES uptake
Studies were carried out to explain the  mechanism of the reduction of the RES uptake and
especially the liver uptake and the simultaneous increase in blood circulation time and
increased distribution into  other organs and  tissues. Hydrophilicity of the particles
definitively plays an important role. However, hydrophilicity does not explain all in vitro
and all body distribution data. Tröster and Kreuter (1988) determined the contact angles of
surfactant solutions on poly(methyl methacrylate) nanoparticles. They observed that low
receding angles were combined with long blood circulation times and a low liver uptake of
particles coated with these surfactants. They challenged their observations experimentally
but they found out the polyoxyethylene(23)laurylether, which fulfils the contact angle
requirement, had no influence on the body distribution on the nanoparticles in comparison
to the uncoated nanoparticles (Tröster et al. 1990; Tröster and Kreuter 1992). 
Other hypothesises to explain the efficacy of surfactants in preventing the liver and RES
were made by Illum at al. (1986). They suggested that an increasing length of the
hydrophilic   polyoxyethylene   chains   protruding   into   the   aqueous   serum   phase,   and
consequently   the   increasing   thickness   of   the   hydrophilic   coat,   would   reduce   the
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opsonization and subsequently the RES uptake by steric stabilization. 
Carstensen et al. (1991), Wesemeyer et al. (1993), and Tröster et al. (1992b) later observed
that in the case of poloxamers an increased polyoxyethylene chain length and coating layer
thickness indeed reduced the hydrophobicity as well as the RES uptake.
Presently the mechanism of the reduction of the RES uptake and the increase in blood
circulation time is not totally explained. 
2.6 Nanoparticles drug release
2.6.1 Background
Drug release from biodegradable polymeric nanoparticles depends on the Fickian diffusion
through the polymer matrix and on the degradation rate of the polymer. The prediction of
the release profile is complex because it results from a combined effect of various
parameters: solid-state drug polymer solubility  (Panyam  et al. 2004) and drug-polymer
interactions (Niwa et al. 1994, Perracchia et al. 1997, Lee et al. 2004, Ubrich et al. 2004),
polymer degradation rate (Horisawa et al. 2002), block copolymer molecular weight and
polydispersity (Matsumoto et al. 1999), water uptake by nanoparticles (Quellec et al. 1999)
and drug solubility in the biological medium. In most studies, in vitro release profiles are
characterized by an initial fast release (burst) of drug close to or at the surface followed by
a sustained release (Perracchia et al. 1997, Matsumoto et al. 1999, Ubrich et al. 2004).
Removing the low molecular weight fraction from the polymer was shown to reduce the
initial burst of drug release (Matsumoto et al. 1999). Depending on formulations in vitro,
drug releases last from a few hours (Allemann et al. 1993, Perracchia et al.1997, Ubrich et
al. 2004) or a few days (Dong et al. 2004) to several weeks (Allemann et al. 1993, Fishbein
et al. 2004, Horisawa et al. 2002, Feng et al. 2004). 
2.6.2 Release Mechanisms
Nanoparticles exhibit their special drug effect  in most cases by direct interaction with their
biological environment (Diepold et al. 1989; Kreuter 1983d). Drug release may occur by
different mechanisms.
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2.6.2.1 Diffusion 
Diffusion occurs when a drug or other active agent passes through the polymer that forms
the controlled-release device. The diffusion can occur on a macroscopic scale — as
through pores in the polymer matrix — or on a molecular level, by passing between
polymer chains. 
2.6.2.2 Nanoparticles matrix erosion
The release of the drug by nanoparticle erosion occurs in case of biodegradable polymers.
These materials degrade within the body as a result of natural biological processes,
eliminating the need to remove a drug delivery system after release of the active agent has
been completed. 
Most biodegradable polymers are designed to degrade as a result of hydrolysis of the
polymer  chains  into  biologically  acceptable,   and  progressively  smaller,  compounds.
Degradation may take place through bulk hydrolysis, in which the polymer degrades in a
fairly   uniform   manner   throughout   the   matrix.   For   some   degradable   polymers   the
degradation occurs only at the surface of the polymer, resulting in a release rate that is
proportional to the surface area of the drug delivery system. 
2.6.2.3 Desorption of surface-bound drug
The release of drugs adsorbed onto the particles surface is usually faster and the burst
release higher compared to encapsulated drugs since only desorption and diffusion process
have to take place but no degradation of the polymer (Brasseur et al. 1991). The release of
the adsorbed drug depends on the affinity of the drug to the particle surface and to the
release medium (Wood et al. 1985, Fresta et al. 1996). 
2.6.3 Study of drug release in vitro 
The release rate of drugs from nanoparticles is strongly influenced by the biological
environment. For example the coating of particles by plasma proteins (Kreuter 1983c) can
create an additional barrier and lead to a retardation of the release, or the interaction with
- 29 -Introduction
biological membranes can lead to an enhanced delivery of drugs though these membranes
(Kreuter 1983d, Diepold et al. 1989). As a consequence, the in vitro drug release may have
very little in common with the delivery and release situation in vivo as frequently observed
(Harmia et al. 1986, Diepold et al. 1989). 
The characterization of the  in vivo  drug release from a colloidal carrier is difficult to
achieve. This can be attributed to the inability of effective and rapid separation of the
particles from the dissolved or release drug in the surrounding solution.
The common methods for determining  the in vitro release are the following:
- Side by side diffusion cells with artificial or biological membranes (Harmia et al. 1986,
Diepold et al. 1989, Kreuter et al. 1983d, Cappel and Kreuter 1991).
- Dialisys bag diffusion techniques (Krause et al. 1986, El-Samaligy 1986, Watanabe et
al. 1978, Malaiya and Vyas 1988).
- Reverse dialysis sac techniques (Cappel and Kreuter 1991).
- Ultracentrifugation (Krause et al. 1986).
- Centrifugal ultrafiltration techniques (Magenheim and Benita 1991).
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2.7 Isotope and devices detecting radioactivity 
2.7.1 Carbon-14
Carbon-14 is a radioactive isotope of carbon discovered on 27
th February, 1940, by Martin
Kamen and Sam Ruben (Kamen er al.1985). 
Its nucleus contains 6 protons and 8 neutrons. Its presence in organic materials is used in
radiocarbon dating. It occurs naturally and has a relative abundance of 0.001 %. The half-
life of carbon-14 is 5730 years. It decays into nitrogen-14 through beta-decay. 
b
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 It is produced in the upper layers of the troposphere and the stratosphere by thermal (low
energy) neutrons absorbed by nitrogen. It can also be produced in ice by high-energy
neutrons causing spallation reactions in oxygen.
Carbon-13 Isotopes of Carbon Carbon-15
Produced from:
Nitrogen-18
Boron-14
Decay chain
Decays to:
Nitrogen-14
 
2.7.2 Liquid scintillation counting
Liquid scintillation counting is a standard laboratory method in the life-sciences for
measuring radiation from beta-emitting nuclides. Scintillating materials are also used in
differently constructed counters in many other fields.
Samples are dissolved or suspended in a "cocktail" containing an aromatic solvent
(historically benzene or toluene, but more recently less hazardous solvents have come into
favor) and small amounts of other additives known as fluors. Beta particles emitted from
the sample transfer energy to the solvent molecules, which in turn transfer their energy to
the fluors; the excited fluor molecules dissipate the energy by emitting light. In this way,
each beta emission (ideally) results in a pulse of light. Scintillation cocktails often contain
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additives that shift the wavelength of the emitted light to make it more easily detected.
The samples are placed in small transparent or translucent (often glass) vials that are
loaded into an instrument known as a liquid scintillation counter. The counter has two
photomultiplier tubes connected in a coincidence circuit. The coincidence circuit assures
that genuine light pulses, which reach both photomultiplier tubes, are counted, while
spurious pulses (due to line noise, for example), which would only affect one of the tubes,
are ignored.
Counting efficiencies under ideal conditions range from about 30 % for Tritium (a low-
energy beta emitter) to nearly 100 % for phosphorus-32, a high-energy beta emitter. Some
chemical compounds (notably  Chlorine  compounds) and highly colored samples can
interfere with the counting process. This interference, known as "quenching", can be
overcome through data correction or through careful sample preparation.
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3 Materials and Methods
3.1 Nanoparticles
3.1.1 Materials
3.1.1.1 Chemicals
Dextran   70   000…………….…………………………………………Sigma,Dreisenhofen
Doxorubicin hydrochloride (Adriablastin
®)…………..…………………. Sicor, Rho-Milan
D(-)Mannitol……………………………………………………………… Merk, Darmstadt
n-butyl-2-cyanoacrylate………..……….…………………………....Sichelwerte,
Hannover 
iso-butyl-2-cyanoacrylate……………………………………………Sichelwerte, Hannover
1N sodium hydroxide................................................................................. Merck, Darmstadt
3.1.1.2 Instruments
Becker……………………………………………………...…………………. Schott, Mainz
Freeze dryer…....................................................................................  LYOVAC
® GT 2, Koln
Glasfilter……………………………………………………………………......
Schott,Mainz   Pipettes...………………………………………………………………
Eppendorf, Hamburg 
Stirrer.................................................................................................................IKA
®, Staufen
3.2 Nanoparticles preparation 
3.2.1 Poly(butyl cyanoacrylate) nanoparticles
Poly(butyl cyanoacrylate) nanoparticles were prepared by emulsion polymerisation. The
cyanoacrylate   monomers   were   added   to   the   aqueous   polymerisation   medium   in   a
concentration of 1 % (w/v) (Kreuter 1992). Because the solubility of the cyanoacrylate
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monomers were exceeded at this concentrations, monomer droplets were formed and the
system had to be stirred permanently. These droplets acted as monomer reserves and single
molecules of monomer were progressively released to form the polymeric chain. The
polymerisation mechanism is an anionic process initiated by OH
- ions resulting from the
dissociation of water. This OH
--induced polymerisation is very rapid. For this reason the
reaction was carried out at pH 2 using an aqueous solution of 0.01 HCl (pH 2). To avoid
the agglomeration of growing particles, it was necessary the addition of Dextran 70 000 in
the concentration of 1 % (w/v) as sterical stabilizer (Douglas et al. 1984, 1985). Particles
adsorb dextran from the solution and the sterical interaction between the particles prevents
their agglomeration. The polymerization was stopped after 4 h neutralizing with 0.1N
NaOH in the amount necessary to obtain a suspension of pH 7. The nanoparticle
suspension was filtered through a sintered glass filter G2 (pore size of 90-150 µm) to
remove polymer residuals. The final suspension of nanoparticles was lyophilised in vials of
1-2 ml with the addition of 3  % mannitol as cryoprotector.
3.2.2 Doxorubicin poly(butyl cyanoacrylate) nanoparticles
Doxorubicin poly(butyl cyanoacrylate) nanoparticles (DOX-PBCA NP) were prepared by
anionic   polymerisation   as   previously   described   (paragraph   3.2.1).   Doxorubicin
hydrochloride was added as a solution to the mixture to obtain a final concentration 0.25
%. The polymerisation process was carried out for 2.5 h instead of 4 h in order to prevent
the degradation of doxorubicin in the acid medium. 
   
3.2.3 Different formulations of doxorubicin poly(butyl cyanoacrylate) nanoparticles
Different formulations of doxorubicin nanoparticles were prepared and characterized
changing the parameters of normal procedure (paragraph 3.2.2) in order to  obtain
nanoparticles with a higher content of bound doxorubicin.
The changed parameters were the following:
pH: Nanoparticles were prepared at different pH (pH 2,  pH 3, pH 4) to compare the
loading of the DOX-PBCA NP obtained.
Concentration of n-butylcyanoacrylate : Concentration of 0.75 % w/v , 0.5 % w/v, 0.25 %
w/v of n-butylcyanoacrylate were used instead of 1 % w/v of n-BCA.
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Type of monomer: DOX-PBCA NP were prepared using iso-butylcyanoacrylate instead of
n-butylcyanoacrylate. The concentration of iso-BCA used was 1 % w/v.
Concentration of dextran: 2 % w/v, 1 % w/v, 0.5 % w/v solutions of dextran were used to
prepare DOX nanoparticles.
Type of steric stabilizer: 1 % w/v solution of Pluronic F 68 was used as steric stabilizer
instead of 1 % w/v solution of dextran 70 000.
Polymerization time: the process of polymerization war prolonged to 4 h in presence of
DOX. Moreover DOX was added into the medium before the monomer.
3.3 Nanoparticles characterization
3.3.1. Size
3.3.1.1 Principle
Size is one of the most important feature of nanoparticles. Other parameters, such as
molecular weight and density, influence nanoparticles release and degradation properties,
whereas charge, surface, hydrophilicity, and hydrophobicity influence the interaction with
the biological environment.
The size was determined by photon-correlation spectroscopy (PCS) or dynamic light
scattering. Photon-correlation spectroscopy determines the hydrodynamic diameter of the
nanoparticles via Brownian motion, which requires knowledge of the exact viscosity of the
medium.
3.3.1.2 Equipment 
PCS....................................................................... Malvern Zetasizer 3000HSA, Worcs, U.K.
3.3.1.3 Working parameters 
Scattering angle………..…………………………………………………………………90°
Temperature………..…………………………………………………………………….25°
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Viscosity……….………..………………………………..………………………..0.01 poise
Refractive index…………………………………………………………..…………….1.333
3.3.1.4 Size determination
Particle size and polydispersity of the size distribution was measured after dilution of the
NP suspension approx. 1 : 40 with Milli-Q water using a Malvern Zetasizer. 
3.3.2 Doxorubicin assay
3.3.2.1 Principle
Assay of doxorubicin in the freeze-dried formulation was performed by spectrophotometry
after dissolution of poly(butyl cyanoacrylate) and doxorubicin.
3.3.2.2 Equipment
Spectrophotometer……………………………..UV-DU 800, Beckmann Coulter, Hannover
3.3.2.3 Procedure
3.3.2.3.1 Calibration curve
Accurately weighed quantities of doxorubicin hydrochloride were dissolved in a mixture of
water - DMF (2 : 7) to obtain solutions with known concentrations in the range of 10 - 60
mg/ml. The spectra of these solutions were registered against the same mixture, and
absorption   was   measured  in   the   maximum   at  480   nm  by  spectrophotometer.   The
calibration graph was plotted. 
3.3.2.3.2 Sample preparation
2 ml of DMF was transferred into a vial with the freeze-dried formulation. The vial was
placed in the ultrasonic bath for 15 min, then 3 ml of mixture water - DMF (2 : 7) was
added, and the vial was stored at room temperature for 1 h to ensure polymer dissolution.
Then the content of the vial was quantitatively transferred into 50 ml volumetric vessel and
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diluted to the volume with the mixture water - DMF (2 : 7). 5 ml of this mixture were
transferred into a 50 ml volumetric vessel and diluted to the volume with the same mixture
(= sample solution). The absorbance of the sample solution was measured and the
concentration of doxorubicin in the sample was calculated using the calibration graph.
The amount of doxorubicin in the vial (Ct) is calculated as follows:
Amount of doxorubicin in the vial (mg) = Ct = 
2 1000
10 10 5 Cs Cs
=
´ ´ ´
,
where
Cs =  concentration of doxorubicin in the sample (mg/ml)
3.3.3 Drug loading
3.3.3.1 Principle
Drug loading is a relative amount of drug bound to the nanoparticles. Drugs are bound to
the nanoparticles mainly by absorption, that is an equilibrium process and usually some
amount of the free drug remains in the medium. Hence this parameter reflects the efficacy
of drug sorption into the polymer matrix. The method of choice for the determination of
drug loading is the separation of the particles by ultracentrifugation and following
quantitative analysis of the free drug in supernatant. 
Drug loading was assessed in the lyophilized formulation after reconstruction. The assay of
free doxorubicin was performed by spectrophotometry and by HPLC and the results of the
two methods were compared.
3.3.3.2 Determination by spectrophotometer
3.3.3.2.1 Equipment 
Spectrophotometer……………………………..UV-DU 800, Beckmann Coulter, Hannover
Centrifuge…………………………..……………………..…5415 D, Eppendorf, Hamburg
Microcentrifuge Filters…..MWL 100,000 Da, Polysulfone membrane, Sigma, Deisenhofen
3.3.3.2.2. Calibration Curve
Accurately weighed quantities of doxorubicin hydrochloride were dissolved in water to
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obtain solutions with known concentrations in the range of 1 - 25 µg/ml. The spectra of
these solutions were measured against water, and the adsorption was determined at the
maximum of 480 nm using a spectrophotometer.
3.3.3.2.3 Sample preparation
The contents of the vials with the lyophilised DOX NP were reconstituted in 2 ml of water.
200 µl of resuspended nanoparticles were transferred to a microcentifuge filter, and
centrifuged for 40 min at 13 200 rpm. 100 µl of clear supernatant was carefully evacuated
with a pipette and diluted 100 - fold with water. The spectra of the samples were recorded
against water, and the adsorption was measured in the maximum at 480 nm. 
Relative drug loading (% of total amount) was calculated by subtraction of the free drug
amount in the supernatant from the total amount in the vials.
Relative drug loading is calculated as follows:
% drug loading = Ct-(Cf /10) /Ct x 100%,
where
Ct= concentration of total doxorubicin used to prepare nanoparticles (mg/ml)
Cf= concentration of doxorubicin in the sample solution (µg/ml).
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3.3.4.2 Determination by HPLC
3.3.4.2.1 Equipment
Liquid chromatograph…………………..……………..D-7000, Merck-Hitachi, Darmstadt
Packing……………………………….LiChrospher® 100 RP-18 (5µm), Merck, Darmstadt
Column…………..……………LiChroCART® 250-4 HPLC-Cartridge, Merck, Darmstadt
Guard column…….……………………….…………LiChroCART® 4-4, Merk,Darmstadt
3.3.4.2.2 Working parameters
Flow rate………….………………………………………………………………0,8 ml/min
Detector wavelength….…………………………………………….……………….. 250 nm
Injection volume …………………………………………………….………………..  20 µl
Temperature………………………………………………………….…………….. ambient
Mobile phase………….. mixture of phosphate buffer (pH 1.4; 0.01M) acetonitrile (60:40)
3.3.4.2.3 Calibration curve
Accurately weighed amounts of doxorubicin were dissolved in 5 ml of the mobile phase.
This solution was further diluted with the mobile phase to obtain solutions with known
concentrations in the range of 1 – 25 µg/ml. The chromatograms of these solutions were
registered and the peak areas were measured.
3.3.4.2.4 Sample preparation
The procedure for the sample preparation was the same as for the samples measured by
spectrophotometer (3.3.3.2.3). 
Peaks area were measured and the amount of doxorubicin in the samples was estimated.
Calculation of relative drug loading by HPLC was described above (3.3.3.2.3). The percent
of drug loading was measured for DOX PBCA NP prepared as usual (3.2.2)  and for
different formulations of DOX NP by spectrophotometer and by HPLC.
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3.3.5 Yield (gas chromatography) 
3.3.5.1 Equipment
GC system………..……….……………HP5890 Series II, Hewlett Packard, Bad Homburg
Column…………..……………..Fused Silica Capillary Column, Permabon-FFAP-DF-0,1
                                                                              5 m x 0,25 mm ID, Machery-Nagel, Düren
3.3.5.2 Working parameters
Injector-temperature……….…………………. 250°C (split / splitless HP 19251 – 60540)
Detector (FID)……………………………………………………….. temperature: 250°C
Oven temperature……................. (gradient) 45°C (3 min)  10°C 1/min  130°C (4 min)
Gas:
- Aux gas: Helium 5.0
- Column flow: 1.0 ml / min
- Split flow: 10.0 ml /min
- Septum flow: 1.1 ml / min
- Column + Aux: 35 ml / min
- Column + Aux + Air : 430 ml / min
- Column + Hydrogen + Aux: 65 ml / min
- Column head pressure : 94 kPa
3.3.5.3 Procedure
The polymerisation yield was measured by means of gas chromatography (GC) as
described by Langer et al. (1994, 1997). 0.5 ml of NP suspension were mixed with 0.5 ml
of 2 N NaOH and shaken overnight at room temperature to hydrolyse to polymer. 50 µl of
this solution were mixed with 50 µl of internal standard (pentanol approx. 0.5 %,
accurately weighted) and diluted with 900 µl of Milli-Q water. 500 µl of this dilution were
extracted with 1000 µl of methylene chloride. The methylene chloride was dried with
water-free sodium sulphate and 1 µl of the sample was injected into the GC system.
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3.4 Nanoparticles release studies
3.4.1 Background
The drug release studies present difficulties due to the small size of particles. Therefore it
is necessary optimise the system of drug release. 
Different methods are necessary to determine the drug release, considering that the
contemporary drug release assessment is possible only for determinate drugs. These
methods are:
- Filtration through small porosity filters 
- Dialyse
- Ultracentrifugation
By all the procedures mentioned exists the problem that during the estimation of the drug
released, the process of drug release continues. The exact kinetic of drug release is not
possible by fast release process. 
Although the extreme difficulty to realize the optimal drug release system, this study was
performed.  
 
3.4.2 Materials
Dyalisis   Tube……………………………….…Spectra/Por  
Ò  CE,   Irradiated
DispoDialyzer
  Spectrum   Laboratories   Inc,  Breda,
Netherlands 
Microtubes…………….…………….……………… Safe-seal micro tube 2 ml, Nümbrecht
Microcentrifuge Filters…………..…………… Ultrafree  -Mc 100 000 NMWL Filter Unit
                                                                                   Millipore Corporation, Bedford, U.S.A.
3.4.3 Methods
The release of DOX from nanoparticles was studied. Different methods were used to
evaluate the kinetics of drug release. These are described as follows:
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3.4.3.1 Dialysis membrane
1 ml of nanoparticles was diluted with 4 ml of water and the total amount of 5 ml was
transferred to a dialysis tube (MWCO 300 000). The content of doxorubicin introduced in
the dialysis tube was 0.5 mg/ml. The dialyse occurred against 54 ml of 0.9 % NaCl
solution. This volume was chosen to reach a detectable doxorubicin concentration. The
maximal concentration that could be detected was 46.3 mg DOX/ml. At various intervals (5
min, 10 min, 15 min , 30 min, 45 min, 1 h, 2 h, 4 h, 8 h) 1 ml of the dialysis solution was
sampled. The concentration of drug was measured by HPLC.
The release studies by dialysis membranes were performed for the following preparations:
standard preparation of  DOX-PBCA NP, DOX-PBCA NP with improved loading, NP
polymerised with the monomer iso-BCA, DOX solution.
3.4.3.2 Microtubes
1 ml of doxorubicin nanoparticles was transferred into a glass beaker containing 53 ml of
NaCl 0.9 %. The maximal doxorubicin concentration attainable was 46.3 mg DOX/ml. This
concentration was required to compare the release results by dialysis membranes and by
microtubes. At intervals of 5 min, 10 min, 15 min , 30 min, 45 min, 1 h, 2 h, 4 h, 8 h, 1 ml
of  solution was taken and introduced into a microtube. The samples were centrifuged for 5
minutes and the surnatants were analysed by HPLC. The results obtained with these
methods were not reliable and therefore only the release study of one nanoparticles
formulation (standard preparation of DOX-PBCA NP, paragraph 3.2.2) was conducted.
3.4.3.3 Microcentifuge filters
The procedure was similar to microtubes (3.4.2.2). Microcentrifuge filters (MWCO
100000)   were   filled   with   0.3   ml   of   solution,   and   the   filtrate   was   analysed  after
centrifugation by HPLC. Due to the unreliability of this method, the study was performed
only for the standard preparation of doxorubicin nanoparticles (3.2.2). 
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3.5 Study of body distribution after intravenous particles injection in rats
3.5.1 Materials
Butyl-2-cyano[3-
14C]acrylate nanoparticles……..Amersham Biosc, Buckinghamshire, UK
1-ml insulin syringe………....................................................Benson  &  Dickson, Dublin
Irland Glue..............................Turbo 2000 Kleber Universal, Boldt & Co, Wermelskirchen
Pentobarbital…………..……………………………………………..Merial , Helbergmoos
Polysorbate 80 (Tween
Ò 80)………………..……………………………..….. Fluka, Buchs
Physiological solution…….………..…………...……. Ampuva
Ò, Fresenius, Bad Homburg
Standard rat diet..................................................................... Harlan-Winkelmann, Borchen
Stereotactic device…………………………………………….… Leitz, Wetzlar Tuberculin
Syringe……...…………….................................………………………B.   Braun,
Melsungen 
Ultrasonicator...................................................Brasonic   12   Europa   B.V,   Soest,
Netherlands
3.5.2 Animals 
The animals used are Wistar-Rats. They were provided from Harlam Winkelmann GmgH,
Borchen, Germany. The animal experiments were performed in accordance to the Russian
Guidelines for Animal Experiments and authorized by the Russian Ministry of Health
(1045-73 and 52-F3-24.04.95)  or the German Tierschutzgesetz and the Allgemeine
Verwaltungsvorschrift zur Durchführung des Tierschutzgesetzes and were authorized by
the Regierungspräsident Darmstadt (II 25.3 – 19 c 20/15 – F 31/10).
3.5.3 Animals keeping
The rats were kept at 24 ± 2 °C and at 55 ± 10 % of humidity. They were acclimatized for 1
week and caged in groups of five. They were fed ad libitum with standard laboratory food
and water.
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3.5.4 Choose of animals 
Four male rats with body weight between 180 - 220 were used for the injection of each
preparation at each time point.
3.5.5 Tumour model system  
The employed 101/8 tumour-cell-line came from the laboratory of A.S. Khalansky,
Institute of  Human  Morphology,  Moskow,   Russia.  The tumour  cells  were  initially
produced by local injection of an a-di-methylbenzanthracene (DMBA) pellet into a rat
cerebellum and maintained by continuous passages by intracerebral implantation. For long-
term storage the tumour tissue was kept at –196°.
3.5.6 Tumour inoculation 
For tumour implantation, animals were deeply anesthetized by intraperitoneal injections of
pentobarbital (50 mg/kg) and then placed in a stereotactic device. Through a midline
sagittal incision, a burr hole of 1.5 mm in diameter was made with a dental drill at a point 2
mm posterior to the right coronal suture and 2 mm lateral to the sagittal midline. Tumour
material (approx. 10
6 cells) from the frozen stock was introduced into a tuberculin syringe
linked to a 21-gauge needle. The tip was placed 4 mm below the bone surface and the
tumour tissue was injected into the bottom of the right lateral ventricle. The scalp incision
was sewn or closed with glue. After development of pronounced clinical signs of the
disease (usually day 14) the animals were sacrificed by carbon dioxide asphyxiation, then
decapitated. The brain was immediately removed. The tumour was excised and chopped
with a scalpel; a tumour implant (5 mg) was inoculated into the brain of new experimental
animals,   as   described   above.   The   appropriate  coordinates   were  confirmed   and   the
technique refined by repeated pilot experiments.
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3.5.7 Preparation of the injection formulations
3.5.7.1 Suspension of empty butyl-2-cyano[3-
14C]acrylate (
14C-PBCA) nanoparticles
40 mg lyophilized particles were reconstituted in 4 ml of physiological solution and
ultrasonicated for about 30 min at 50 kHz in a bath type ultrasonicator. In order to obtain
loaded doxorubicin nanoparticles by adsorption, the labeled nanoparticles were dispersed
in a doxorubicin solution (0. 45 mg/ml) and stirred over night.
3.5.7.2 Preparation of polysorbate 80-coated  
14C-PBCA nanoparticles 
The lyophilized particles (40 mg) were resuspended in 3.6 ml of physiological solution.
After ultasonicating particles for 30 min, 400 ml of 10 % (v/v) polysorbate 80 solution was
added and the mixture was incubated for 30 min.
3.5.7.3 Preparation of doxorubicin-loaded 
14C-PBCA nanoparticles
In   order   to   obtain   loaded   doxorubicin   nanoparticles   by   adsorption,   the   labelled
nanoparticles were dispersed in a doxorubicin solution (0.45 mg/ml) and stirred over night.
Then polysorbate 80 was added to give a final solution of 1 % (v/v) and the mixture was
stirred for 30 min. 
3.5.8 Particles characterization
3.5.8.1 Zeta potential
In order to study the influence of plasma, 
14C-PBCA nanoparticles, polysorbate 80-coated
nanoparticles, and DOX-loaded nanoparticles, were incubated in undiluted Wistar rat
plasma at 37 °C. The concentration of doxorubicin was 0.3 mg (corresponding to 6.7 mg of
PBCA nanoparticles) /10 ml of serum, simulating a single injection of 1.5 mg/kg
doxorubicin to a rat. After 30 min, the incubation medium was ultracentrifuged (145 000 ´
g, 1 h, 4 °C) and the nanoparticles pellet was redispersed in water. The size and surface
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charge (zeta potential) were then determined and compared with the values obtained before
incubation.
3.5.8.2 Charge 
The mean particles diameter was determined by photon correlation spectroscopy (PCS). 
3.5.8.3 Loading
To determine the doxorubicin entrapment efficiency, lyophilized DOX nanoparticles were
resuspended in water, and the particles were separated from the solvent by centrifugation.
Concentration of free DOX dissolved in supernatant was determined by HPLC. Relative
drug loading (% of total amount) was calculated by subtraction of free drug in the
supernatant from the total amount in the vials.
The assessment of drug loading was described in detail in paragraph 3.3.3.2.
3.5.9 Injection of nanoparticle suspensions in rats 
The injections were performed with a 1-ml insulin syringe. The nanoparticle preparation
was injected i.v. to group of four rats. The nanoparticle preparations - uncoated particles,
coated and doxorubicin loaded particles - were injected into the lateral vein (3.33 ml/kg
body weight) at the rate of 1.5 ml/min using a sterile canula lock No. 18. The dose was
1000 MBq/Kg body weight.
3.5.10 Sacrifice of rats 
3.5.10.1 Healthy rats
Animals were placed in CO2 chamber 10 min, 1 h, 6 h, 24 h, 3 days, 1 week, 4 weeks after
injection until narcosis. Finally they were sacrificed by decapitation.   
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3.5.10.2 Tumour bearing rats
The injections were performed on day  5
th, 8
th, 10
th post tumour implantation. The animals
were killed by CO2 chamber and decapitated 10 min, 1 h, 6 h, 24 h, after injection.
  
3.5.11 Preparation of organs
After decapitation, blood was collected, the abdomen and chest were opened and liver,
lungs, heart, kidneys, spleen, gonads, brain were removed. Two samples were taken from
each organ and weighed. The weight range of the samples was of 80 - 130 mg per vial.
The tail was also assayed for residual radioactivity in order to allow the quantification of
the injected i.v. dose. The whole tail was dissected into 6 parts that were assayed using the
same conditions as for the other organ samples.
3.5.12. Assessment of organs radioactivity
3.5.12.1 Chemicals
Tissue solubilizer......................................................................BTS-450, Beckman, München
Ready organic scintillation cocktail……………….…………..………. Beckman, München
Acetic acid .…………………………………………………….August Hedinger, Stuttgart
Hydrogen peroxide 30 %……...………………………………. August Hedinger, Stuttgart
3.5.12.2 Instrument
Liquid scintillation counter……………………Wallac 1409 DSA, PerkinElmer, Jügesheim
3.5.12.3 Determination of the activity of the injection suspensions
100 ml of each injection preparation were taken and the radioactivity was determined by
scintillation counter.
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3.5.12.4 Preparation of samples and measurement of radioactivity
1 ml tissue solubilizer was added and the vials were stored at 50 °C until all tissue was
solubilized. For tail samples 3 ml of tissue solubilizer were added. 30 % H2O2 was added
until the colour disappeared. The addition of glacial acetic acid (70 ml) was necessary to
reduce the pH and minimize the possibility of chemo luminescence. After the addition of
10 ml scintillation cocktail, the samples were stored for about one week in  darkness. The
radioactivity was counted in a scintillation counter. The total radioactivity in the tail was
subtracted from the total dose in order to calculate the radioactivity of the organs. 
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3.6 Chemotherapy studies  
3.6.1 Chemicals
Polysorbate 80 (Tween
Ò 80)………..……………………………..………..… Fluka, Buchs
Poloxamer 188 (Pluronic
â F 68)……………………….………….….BASF, Ludwigshafen 
Poloxamine 908 (Symperonic
â  T908)……………..………….……..BASF, Ludwigshafen 
3.6.1.1 Polysorbate 80 (Tween
Ò 80)
Polysorbate 80 is a relative homogenous viscous liquid (270-430 centistokes). The base
chemical name of the major component of Tween
Ò  80 is polyoxyethylene-20-sorbitan
monooleate (Fig 3.1) which is structurally similar to the polyethyleneglycols. 
Figure 3.1. Chemical structure of polysorbate 80.
Like most non-ionic surfactants, Tween
Ò 80 is capable of forming micelles in aqueous
solution with critical micellar concentration of 0.01% (weight/volume) in protein-free
aqueus solution (Tije et al. 2003).  The chemical-physical properties of  Tween
Ò 80 are
summarized in Tab 3.I.
Phisical-chemical characteristics
Form viscous liquid
Color jellow pale
Density Ca. 1.08 g/cm
3 25 °C
Viscosity 425 mPa.s 25 °C
Boiling point >100 °C
Solubility in water soluble
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Solubility in other solvent Soluble in ethanol and iso-
propanol
Acute Toxicity LD50 (rats) > 38g/Kg
Tab 3.I
3.6.1.2 Poloxamer 188 (Pluronic
â F 68, Pluronic
â  PE 6800)
         
Poloxamers consist of a central polyoxypropylene molecule, which is flanked on both sides
by two hydrophilic chains of polyoxyethylene (Fig 3.2). Poloxamer 188 has an average
molecular weight of 8400 (Tab 3.II). 
Figure 3.2. Chemical structure of poloxamer 188.
This molecule possesses  haemorheological activities, has antithrombotic  properties, is
capable to stimulate the phagocytosis and the production of superoxide anion. Moreover, it
provokes neutrophil degranulation and cell membrane sealing (Moghimi and Hunter 2000).
Phisical-chemical characteristics
Form Cast Solid / Prill / Pastille
Average molecular weight 8400
Viscosity, cps at 77 °C 1000
Melting point 52 °C
Cloud point (1% aqueus) >100 °C
Solubility in water  >10 % at 25 °C
pH (2,5% aqueus)  5.0-7.5
Tab 3.II
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3.6 .1.3 Poloxamine 908 (Symperonic
â  T908)
Poloxamines   are   tetrafunctional   block   copolymers   with   four  polyoxypropylene–
polyoxyethylene  blocks joined together by a central ethylene diamine bridge (Fig 3.3).
Poloxamines   adsorb   strongly   onto   the   surface   of   hydrophobic   nanospheres   [e.g.
polystyrene, poly(lactide-co-glycolide), poly(phosphazene), poly(methyl methacrylate) and
poly(butyl 2-cyanoacrylate) nanospheres] via their hydrophobic polyoxypropylene centre
block (Storm et al. 1995).
H(OC2H4)y(OC3H6)x
H(OC2H4)y(OC3H6)x
NCH2CH2N
   (C3H6O)x(C2H6O)yH
(C3H6O)x(C2H6O)yH
Figure 3.3. Chemical structure of poloxamine 908.
Poloxamine 908 characteristics are summarized in the Table 3.III. 
Phisical-chemical characteristics
Form scurfs
Color white
Density 1,14 g/cm
3 77 °C
Melting point 57 °C
Point of combustion >150 °C
Solubility in water >100 g/l 20 °C
pH   8-10 at 20 °C
Table 3.III
3.6.2 Drug treatment
Antitumoural drug-loaded nanoparticles were evaluated for the chemotherapeutic treatment
of glioblastomas. The choose of animals, the tumour model system, and the procedure of
tumour implantation were described in the chapter: “Study of body distribution after i.v.
particles injection” (3.5). 
Tumour bearing rats were used in two different sets of experiments. 
One set received doxorubicin nanoparticles coated with different surfactants (polysorbate
80, poloxamer 188, poloxamine 908) or a solution of doxorubicin. 
The animals of the other set were treated with different formulations of nanoparticles, and
each formulation was coated only with the surfactant polysorbate 80.  A doxorubicin
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solution was used as well. 
These preparations were injected i.v. into the tail vein in the dose regimen of 3 x 1.5 mg/kg
on days 2, 5, and 8 post tumour implantation. The concentration of doxorubicin in the
injection solutions was 0.25 %.
 The period of observation was 180 days post tumour implantation. Then the surviving
animals were sacrificed and necropsied.  The experiments were run in duplicate. 
3.6.2.1 Set 1
3.6.2.1.1 Doxorubicin solution 
A solution of 0.45 mg/ml of doxorubicin hydrochloride was prepared. The amount of
doxorubicin injected to rats was 1.5 mg/kg, and the  volume of solution administrated was
3.33 ml/kg body weight.     
 
3.6.2.1.2 n-PBCA doxorubicin loaded nanoparticles coated with polysorbate 80
Particles   were  prepared  as   described   previously  (3.2.2).   Lyophilized   particles   were
resuspended in physiological solution and ultrasonicated for about 5 min. A determined
amount of polysorbate 80 10 % (w/v) solution was added to obtain a concentration of 1 %.
The mixture was stirred for 30 min to ensure the coating of the particles and the
preparation was injected in the amount of 1.5 mg/Kg of doxorubicin per injection.   
3.6.2.1.3 iso-PBCA doxorubicin loaded nanoparticles coated with polysorbate 80
The polymerisation was carried out using 1 % of iso-butyl(cyano acrylate) instead of 1 %
n-butyl(cyano acrylate). The preparation of the injection solutions is described above
(3.6.2.1.2). 
3.6.2.1.4 PBCA nanoparticles with improved doxorubicin loading (new formulation)
coated with polysorbate 80 
The usual procedure of preparing doxorubicin nanoparticles (3.2.2) was modified in order
to obtain particles with higher content of doxorubicin. The “new formulation” was
prepared as follows: 0.75 % (w/v) of n-butyl(cyano acrylate) was added to 2 % (w/v)
solution of dextran 70 000 in 0.01 N HCl (pH 2) under constant stirring. DOX was added
immediately after the beginning of polymerisation in the concentration of 0.25 % (w/v).
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After 4 h the mixture was neutralized with 0.1 NaOH, filtered, filled in vials (2ml/vial),
and freeze-dried with addition of 3 % (w/v) mannitol as cryoprotector. The preparation of
the injection solution was performed as described in paragraph 3.6.2.1.2.
3.6.2.2 Set 2
3.6.2.2.1 Doxorubicin solution 
A solution of doxorubicin hydrochloride was prepared as described in the paragraph
3.6.2.1.1.  Then doxorubicin solution was injected.
3.6.2.2.2 PBCA doxorubicin nanoparticles coated with polysorbate 80 
PBCA   doxorubicin   nanoparticles   were   resuspended   in   physiological   solution,
ultrasonicated, and a solution of 10 % (w/v) polysorbate 80 was added to the suspension to
reach the final concentration of 1 %. The particles were stirred for 30 min, and the
formulation was injected.   
3.6.2.2.3 PBCA doxorubicin nanoparticles coated with Poloxamine 908
The injection solution was prepared as described above (3.6.2.2.2) using a poloxamine 908
solution instead of polysorbate 80.
3.6.2.2.4 PBCA doxorubicin nanoparticles coated with poloxamer 188
A solution of poloxamer 188 was used to coat PBCA doxorubicin nanoparticles as
described above (3.6.2.2.2).
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3.7 Whole-body autoradiography (WBA) studies
3.7.1 Principle
Autoradiography is a process by which radioactive materials are located by exposure to a
photographic emulsion forming a pattern on the film corresponding to the location of the
radioactive compounds within the cell.  
Studies of WBA were carried out to evaluate the distribution of  [14-
14C] doxorubicin
bound to nanoparticles tissues and organs at certain time points. Moreover the WBA
permitted the determination of sites of accumulation and retention of [14-
14C] DOX PBCA
NP and the assessment of penetration across the BBB. 
3.7.2 Materials and Methods
The autoradiography studies were performed by Sanofi-Aventis, Frankfurt am Main, who
provided devices and chemicals.
[14-
14C] doxorubicin was purchased from Amersham Biosciences, Buckinghamshire, UK.
3.7.2.1 [14-
14C] - Doxorubicin hydrochloride
The molecular weight of the radiolabelled [14-
14C] - doxorubicin hydrochloride is 582 and
the specific radioactivity is 94.5 mCi/mg.
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3.7.3 Preparation of the injection formulations
4 rats of 200 g weight were utilized to perform the WBA studies. 1 ml of the [14-
14C] -
DOX preparation was injected intravenously in each rat. The preparations administrated are
described as follows:
3.7.3.1 [14-
14C] Doxorubicin solution + polysorbate 80
Cold DOX and  [14-
14C] -  DOX were blended and dissolved in a solution of 1 %
polysorbate 80 in order to obtain 1 ml of solution containing 0.3 mg/ml DOX and 22.5
µCi.
3.7.3.2   [14-
14C]   Doxorubicin   poly(butyl   cyanoacrylate)   nanoparticles   coated   with
polysorbate 80
The procedure to prepare DOX PBCA NP was described in the paragraph 2.3.3. 
The amount of each reagent was accurately weighted in order to obtain the limited NP
volume of 3 ml. Briefly, 25 mL of BCA were added to 2.5 ml of 1 % dextran solution at pH
2. After 30 min, 90 µl of [14-
14C] – DOX + DOX solution were added. The polymerization
process was carried out for 2.30 h and it was stopped by addition of  244 mL NaOH 0.1 N. 
For the NP coating, 300 mL of polysorbate 80 10 % (w/v) were added to give a final
solution of 1 % (v/v), and the mixture was stirred for 30 min. 
3.7.4 Administration of [14-
14C] - DOX preparations 
[14-
14C] - DOX PBCA NP coated with PS 80 were injected i.v. in three rats which were
sacrificed at 1 h, 2 h, 4 h post injection.
[14-
14C] - DOX + PS 80 was injected in only one rat and it was sacrificed at 2 h post
injection. Each rat received the radioactive dose of 22.5 µCi.    
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3.7.5 Section preparation and radioluminograms development
After   scarification   of   rats,   each   carcass   was   snap-frozen   and   set   individually   in
carboxymethyl cellulose. The blocks were sectioned on a cryomicrotome at approximately
–25 °C, and each section was placed on an adhesive tape. The sections were placed on
phosphor imaging plates for a few hours. Scanning each plate with a laser beam allowed to
prepare radioluminograms of high resolution. 
By addition of blood samples fortified with radiolabelled drug in the frozen block, the
amount of radioactivity in each tissue could be quantified by linear calibration. The
phosphor imaging plates were scanned with a state-of-the-art phosphor imaging system
equipped with quantification  software.
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4 Results
4.1 Nanoparticles characterization
Doxorubicin   loaded   to   polysorbate   80-coated   nanoparticles   demonstrated   a   high
antitumour effect against the rat glioblastoma 101/8 (Steiniger et al. 2004). For this reason
the aims of the present study was to investigate the optimization of this formulation by
modification of the reaction parameters. Drug loading, size, and polymerization yield were
determined for each nanoparticles formulation. 
 
4.1.1 Drug loading
Table 4.I summarizes the experimental results with respect to the joint effect of dextrans
and n-BCA concentration, pH values, the polymerization time, and the type of the
monomer on doxorubicin loading in nanoparticles.  It can be seen that the modification of
the parameters used for the standard formulation 0 could not improve the drug loading to a
major extent.  A relevant reduction of drug loading occurred at lower (pH 1, formulation
No 4) and higher pH values (pH 3, formulation No 6, and pH 4, formulation No 7) than pH
2. A slight increase in the drug loading of the particles was obtained by reducing the
concentration of n-BCA from 1% w/v to 0.75 % w/v whereas a further decrease in
monomer concentration to 0.5 % w/v decreased the drug loading to 65.40 %.   The
influence of dextran concentration was not considerable: at the concentration of 0.5 %, the
loading was slightly decreased to 61.5 % (formulation No 4), whereas the increase of
concentration to 2 % produced no significant effect (formulation No 3).  In the standard
formulation, doxorubicin was added to the reaction medium 30 min after the start of
polymerization. However, nanoparticles with similar properties also could be formed at a
n-BCA concentration of 0.75 % combined with a simultaneous increase in stabilizer
(dextran) content to 2 % when the drug was added before the monomer (formulation No 9).
Another butyl cyanoacrylate isomer, iso-butyl(cyanoacrylate), was used instead of n-butyl
(cyanoacrylate) for the synthesis of formulation No 10. This monomer was chosen based
on the data of its lower toxicity, as compared to n-BCA (Kante et al. 1982). 
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Formulation
Dextran
[% w/v] pH
Monomer
concentration
[% w/v]
Reaction time
[h]
Particle size
(SD) [nm]
NP capacity
[mg DOX/mg
PBCA]
Drug loading
measured by
HPLC [%] (SD)
* 
Drug loading
measured by
spectroph. [%]
(SD)*
0 1 2 1 2.30 210 (10.01) 0.33 71.10 (2.59) 53.21 (3.63)
1 1 2 0.75 2.30 208 (12.17) 0.33 72.50 (1.61) 55.34 (2.53)
2 1 2 0.5 2.30 235 (6.24) 0.30 65.40 (4.65) 50.87 (4.68)
3 2 2 1 2.30 205 (17.04) 0.33 73.50 (4.18) 61.5 (4.48)
4 0.5 2 1 2.30 250 (17.21) 0.28 61.10 (2.55) 51.1 (4.12)
5 1 1 1 2,30 251 (26.25) 0.24 58,21 (3,51) 40.21 (3.21)
6 1 3 1 2.30 248 (16.09) 0.24 52.47 (4.43) 42.45 (5.56)
7 1 4 1 2.30 253 (27.87) 0.22 49.23 (4.00) 39.29 (5.56)
8 1 2 1 4.00 218 (20.66) 0.33 72.40 (2.62) 65.21 (2.45)
9** 2 2 0.75 4.00 198 (6.43) 0.35 76.34 (1.78) 69.25 (4.20)
10*** 1 2 1 2.30 215 (10.02) 0.34 73.38 (1.62) 64.25 (2.98)
11
# 1 2 1 2.30 190 (4.1) 0.10 30.20 (2.13)  20.21 (1.58)
* [mg DOX adsorbed/mg tot DOX in the colloidal suspension] x 100
** doxorubicin was added into the medium before the monomer
*** polymerization was carried out utilizing iso-BCA
# Pluronic F68 was used instead of Dextran
Table 4.I
Doxorubicin loaded in n-poly(butyl cyanoacrylate) and iso-poly(butyl cyanoacrylate)  nanoparticles: influence of the reaction variables on the formulation parameters (n = 4). 
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Finally the application of 1 % of pluronic F 68 instead of 1 % of dextran led to a dramatic
reduction of drug loading (Formulation 11).
Noteworthy   is   the   significant   difference   of   the   drug   loading   values   assessed   by
spectrophotometer and HPLC. The loading measured by HPLC was 10 - 20 % more than
the value assessed by spectrophotometer for all the formulations.
The measurements performed by HPLC were supposed to be more reliable. HPLC reduces
the effect of light scattering and is not influenced by turbidity of the samples that can
falsified the measure of concentration. Moreover the reliability of the HPLC measurements
was confirmed by the reduced values of standard deviation (SD) in comparison to the SD
calculated from the spectrophotometer estimations (Tab 4.I).
4.1.2 Particles size     
No considerable size differences were shown between the nanoparticles formulations (Tab
4.I). A smaller NP size was observed for the standard formulation No 0 and for the
formulation No 1, in which the monomer concentration was reduced to 0.75 % (208-210
nm). However a further reduction of the n-BCA concentration to 0.5 % caused the increase
in NP size (235 nm). A size increase of nanoparticles was observed at pH-values of 3, 4, 1
whereas the smallest particles were obtained at pH 2.
4.1.3 Nanoparticle loading capacity
The determination of nanoparticle loading capacity (mg DOX/mg PBCA) was possible
after assessment of the polymerization yield (paragraph 3.3.4). The results are shown in
Table 4.1.
The capacity was reduced at pH values deviating from pH 2. For all the remaining
formulations no significant differences in drug capacity were observed.  
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4.2 Release Studies
Drug release studies were performed with the formulations which showed an increased
loading (Tab 4.I). The formulations selected were: 1) standard formulation (formulation No
0); 2) formulation No 9 (0.75 % n-BCA, 2 % dextran, 4 h polymerization); 3) formulation
No 10 (application of iso-BCA). The characterization of these preparations is shown in Tab
4.I.    
4.2.1 Dialysis membrane  
The drug release curves of the different preparations are shown in Figure 4.1. As shown by
the release curve of doxorubicin solution, more than 30 % of doxorubicin was absorbed on
the   dialysis   membrane.   The   release   of   doxorubicin   for   all   the   formulations   was
characteristically biphasic with an initial fast release phase followed by a second much
slower first-order release phase. 
The release of doxorubicin from the standard formulation No 0 and formulation No 10 was
comparable. 
Formulation No 9 showed a slower drug release in comparison to formulation No 0 and No
10.
DOX NP release: dialysis membrane
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Figure 4.1. Release curves of DOX solution and of formulations 0, 9, and 10 with dialysis membrane.
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4.2.2 Microtubes
The release of doxorubicin from nanoparticles determined using microtubes was extremely
fast, probably due to the high g-force. The results obtained with this method were not
useful for the present study.  
DOX NP release: microtrubes
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Figure 4.2. Release curve of standard formulation 0 with microtube devices.
4.2.3 Microcentrifuge filters
The results with microcentrifuges filters were similar to those obtained with microtubes.
Additionally adsorption of about 30 % doxorubicin on the filters occurred.
DOX NP release: 
microcentrifuge filters
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Figure 4.3. Release curve of standard formulation 0 with microcentrifuge filter devices.
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4.3 Chemotherapy studies
4.3.1 Treatment of rats bearing intracranial transplanted glioblastoma 101/8 using
different nanoparticle formulations of doxorubicin coated with polysorbate 80
Formulations No 9 and No 10 were chosen to evaluate their anti-tumour efficacy in
glioblastoma-bearing rats and compared with the standard formulation No 0.  The rationale
of choosing these formulations for chemotherapeutical studies was their improved loading.
It was reasoned that an higher amount of doxorubicin bound to the particles increased the
quantity of the drug that can be transported into the brain. Moreover, since it was
previously shown that the coating of PBCA nanoparticles with polysorbate 80 (PS 80)
enabled the transport of bound drugs across the blood-brain barrier (BBB) after i.v.
injection (Kreuter 2002), these formulations were coated with PS 80.
As shown in Table 4.I, formulations No 0, 9, and 10 had similar physico-chemical
characteristics, which allowed an adequate comparison of their biological effects at equal
doses. The treatment regimen and the tumour model were chosen based on the results of
previous studies, where the standard formulation No 0 coated with polysorbate 80
demonstrated high anti-tumour effects (Steiniger et al. 2004).
Fig. 4.4 shows the Kaplan-Meier survival curves of the rats exposed to treatment with
various DOX formulations in the present study. It can be seen that the standard formulation
No 0 was the most effective formulation: 35 % (7/20) of the animals treated with
formulation No 0 (Figs. 4.4 and 4.5) survived for 180 days after tumour implantation.
These animals were sacrificed, and no signs of tumour growth were observed after
necropsy. In the groups treated with formulations No 9 and No 10, the percentage of long-
term survivors was 15 % (3/20) and 10 % (2/20), respectively.  Free DOX in solution was
less effective: 10 % of the animals (2/20) survived for 65 days. All control animals died
between day 18 and day 24.
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Fig. 4.4. Influence of nanoparticle polymer and formulation on the survival (Kaplan-Meier plot) of rats
bearing intracranially transplanted glioblastoma 101/8 after i.v. injection of the following doxorubicin
formulations: free doxorubicin in saline (DOX), formulation 0, 9, and 10 in 1 % polysorbate 80 solution.
Treatment regimen: 3 x 1.5 mg/kg on days 2, 5 and 8 post tumour implantation (n = 20; summarized data of 2
experiments).
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4.3.2  Treatment of rats bearing intracranial transplanted glioblastoma 101/8 with
DOX NP PBCA nanoparticles coated with different surfactants
In the second set of experiments, the influence of surfactants on the survival time of
glioblastoma 101/8-bearing rats was investigated. The efficacy of DOX PBCA NP coated
with poloxamer 188 and poloxamine 908 in the treatment of glioblastoma was evaluated
and  compared  with polysorbate 80. As  shown  in Fig. 4.5,  the  standard  reference
formulation – DOX-PBCA nanoparticles coated with polysorbate 80 – again was the most
effective.  The percentage of long-term survivors treated DOX loaded in the nanoparticles
coated with poloxamer 188 or poloxamine 908 was 20 % (4/20). 
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Fig.  4.5.  Influence  of surfactants on the  survival (Kaplan-Meier plot) of rats bearing intracranially
transplanted   glioblastoma   101/8   after   i.v.   injection   of   the   following   doxorubicin   formulations:   free
doxorubicin in saline (DOX), formulation 0 in 1 % solution of polysorbate 80 (PS 80), poloxamer 188 (P
188), or poloxamine 908 (P 908). Treatment regimen: 3 x 1.5 mg/kg on days 2, 5 and 8 post tumour
implantation (n = 20; summarized data of 2 experiments). 
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4.4 Body distribution studies 
4.4.1 Objective of the study
The objective of the present study was to evaluate the body distribution of uncoated,
coated,   and   doxorubicin-loaded  
14C-poly(butyl  cyanoacrylate)  nanoparticles,   utilizing
polysorbate 80 as surfactant in healthy and tumour bearing rats. Attention was particularly
focused on the biodistribution of nanoparticles into the brain.
4.4.2 Healthy Rats 
4.4.2.1 Surface charge
The charge of the particles appears to influence the body distribution. Therefore the zeta
potential of nanoparticles was investigated (Brigger et al. 2004). PBCA NP and PS 80-
coated PBCA NP showed negative zeta-potentials in distilled water, a general phenomenon
of theoretically uncharged polymeric particles (Table 4.II). Adsorption of doxorubicin on
the surface modified the charge of nanoparticles towards a positive value, caused by the
charge of this drug. However, after contact with serum the zeta-potential of these particles
was changed to negative again and was not significantly different from particles without
doxorubicin.  
NP NP+PS 80 NP+DOX NP+PS 80+DOX
Mean diameter [nm] 185 - 200 220 - 260 230 - 280 210 - 250
Polydispersity index < 0.2 < 0.2 < 0.2 < 0.2
Entrapment
efficiency*[%] ~ ~ 59 % 30 %
Drug loading** [%] ~ ~ 5.7 2.9
Surface Charge [mV] -14 -10.2 8 2
*[mg DOX adsorbed/mg tot DOX in the colloidal suspension]x100
** [mg DOX adsorbed/mg BPCA nanoparticles]x100
Table 4.II. Physicochemical properties of poly(butyl cyanoacrylate) nanoparticles.  
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4.4.2.2 Body distribution 
The   body   distribution   of   the   butyl-2-cyano[3-
14C]acrylate   nanoparticles   (
14C-PBCA
nanoparticles) is shown in Table 4.III (percent of dose) and Table 4.IV (µg/g tissue weight)
and in Figs 4.6 - 4.7. 
Time  Sample   NP   NP+PS 80   NP+PS 80+DOX
     
Percent
dose S.D. Percent
dose S.D. Percent
dose S.D.
10 min Blood 11.39 2.66 17.00 4.02 23.00 5.37
Heart 0.62 0.09 0.52 0.15 0.48 0.05
Lungs 12.25 1.50 9.19 1.39 5.70 0.71
Liver 49.99 8.53 41.64 6.98 43.23 3.08
Spleen 4.49 1.12 1.94 0.95 3.41 0.65
Testicles 0.90 0.00 0.90 0.57 0.96 0.19
Kidneys 4.12 0.69 5.84 1.14 6.83 0.27
Brain 0.32 0.02 0.34 0.04 0.39 0.04
1 h Blood 8.17 3.05 9.87 1.80 9.62 2.22
Heart 0.44 0.23 0.67 0.25 0.40 0.11
Lungs 3.30 1.02 6.51 1.69 4.07 1.03
Liver 47.48 9.12 30.59 4.44 48.30 9.10
Spleen 2.25 1.20 1.13 0.99 2.26 0.23
Testicles 0.41 0.10 0.82 0.08 0.80 0.42
Kidneys 3.06 0.46 4.43 0.42 3.06 0.53
Brain 0.34 0.12 0.61 0.04 0.44 0.12  
6 h Blood 1.84 0.27 3.27 0.53 3.18 1.37
Heart 0.63 0.17 0.16 0.01 0.22 0.04
Lungs 2.88 1.18 5.43 0.45 2.00 0.78
Liver 19.54 5.32 16.2 3.77 22.61 3.31
Spleen 0.52 0.58 0.98 0.64 1.89 0.48
Testicles 0.54 0.19 0.37 0.19 0.28 0.05
Kidneys 0.62 0.08 0.93 0.13 0.89 0.15
Brain 0.12 0.02 0.15 0.06 0.19 0.08
24 h Blood 0.96 0.02 1.08 0.03 2.76 0.08
Heart 0.15 0.02 0.12 0.01 0.14 0.02
Lungs 0.60 0.02 0.18 0.01 3.72 0.71
Liver 15.18 0.81 12.76 1.56 21.12 4.57
Spleen 0.21 0.02 0.08 0.11 2.19 0.23
Testicles 0.10 0.00 0.24 0.19 0.38 0.14
Kidneys 0.29 0.03 0.28 0.08 1.25 0.18
Brain 0.07 0.02 0.36 0.12 0.14 0.06
3 days Blood 1.45 0.90 1.29 0.21 0.43 0.30
- 66 -Results
Heart 0.25 0.16 0.12 0.05 0.05 0.11
Lungs 0.05 0.40 0.46 0..37 0.31 0.42
Liver 12.17 1.23 9.71 1.52 4.25 2.41
Spleen 0.88 0.73 0.46 0.38 0.29 0.23
Testicles 0.19 0.06 0.16 0.01 0.07 0.01
Kidneys 0.45 0.25 0.50 0.10 0.20 0.07
Brain 0.07 0.04 0.12 0.03 0.05 0.03
1 week Blood 0.59 0.21 0.67 0.24
Heart 0.12 0.01 0.06 0.02
Lungs 0.40 0.20 0.43 0.25
Liver 9.29 1.98 10.97 2.36
Spleen 0.90 0.54 0.60 0.53
Testicles 0.20 0.04 0.12 0.02
Kidneys 0.53 0.05 0.32 0.12
Brain 0.08 0.03 0.07 0.02
4 weeks Blood 0.64 0.55 0.55 0.1
Heart 0.03 0.02 0.04 0.01
Lungs 0.50 0.30 0.30 0.14
Liver 2.23 0.94 7.94 1.78
Spleen 0.24 0.15 0.53 0.1
Testicles 0.08 0.03 0.11 0.01
Kidneys 0.15 0.04 0.26 0.04
Brain   0.03 0.01   0.05 0.01      
Table 4.III. Body distribution of 
14C as percent of the dose after intravenous administration of  
14C-PBCA
nanoparticles, polysorbate 80-coated 
14C-PBCA nanoparticles, and DOX 
14C-PBCA loaded nanoparticles in
healthy rats.
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Time Sample NP NP+PS 80 NP+PS 80+DOX
µg NP/g S.D. µg NP/g S.D. µg NP/g S.D.
10 min Blood 51.66 12.06 77.11 13.71 104.32 18.30
Heart 37.49 5.44 31.45 6.82 29.03 2.27
Lungs 444.49 54.43 333.45 37.93 206.82 17.21
Liver 247.35 42.21 206.03 25.97 213.90 11.45
Spleen 488.76 121.92 211.18 77.77 371.20 53.17
Testicles 19.59 0.00 19.59 9.26 20.95 3.04
Kidneys 117.95 19.76 167.18 24.55 195.58 5.90
Brain 10.25 0.32 10.89 0.48 12.49 0.48
1 h Blood 37.07 13.83 44.76 8.16 43.64 10.65
Heart 26.57 13.91 40.28 15.12 24.18 6.65
Lungs 119.63 36.95 236.18 40.93 147.58 37.37
Liver 234.94 45.13 151.35 21.97 238.96 45.03
Spleen 245.04 90.21 123.35 51.21 314.92 89.35
Testicles 8.93 2.18 17.85 1.74 17.42 215
Kidneys 87.78 13.18 126.96 12.03 87.60 15.18
Brain 10.89 2.14 19.53 2.60 14.09 2.82
6 h Blood 8.35 1.23 14.83 2.26 14.42 5.72
Heart 38.37 10.36 9.68 0.57 13.30 2.23
Lungs 104.32 43.08 197.15 15.38 72.57 26.14
Liver 96.68 26.51 80.16 17.53 111.87 15.07
Spleen 56.60 23.59 106.68 25.47 205.74 48.07
Testicles 11.65 4.19 7.95 3.91 5.99 0.99
Kidneys 17.69 2.37 26.71 3.46 25.42 4.06
Brain 3.84 0.32 4.80 0.90 6.08 1.18
24 h Blood 4.35 0.96 4.90 0.52 12.52 2.11
Heart 9.25 2.21 7.08 1.50 8.71 2.10
Lungs 21.77 3.09 6.53 2.44 134.98 30.94
Liver 75.11 10.53 63.14 18.25 104.50 40.23
Spleen 22.86 1.11 8.71 3.18 238.39 24.82
Testicles 2.18 0.00 5.12 9.72 8.27 2.70
Kidneys 8.31 1.79 8.16 4.50 35.92 5.82
Brain 2.18 0.83 11.53 4.49 4.48 0.84
3 days Blood 6.58 3.41 5.85 0.92 1.95 1.10
Heart 15.12 8.09 7.26 2.92 3.02 2.93
Lungs 17.69 11.51 16.81 16.33 11.37 32.42
Liver 60.22 5.09 48.04 7.26 21.03 28.60
Spleen 95.79 66.42 50.07 39.95 31.57 18.25
Testicles 4.14 1.03 3.48 0.30 1.52 0.00
Kidneys 12.96 6.09 14.25 2.79 5.73 3.02
Brain 2.24 1.23 3.84 0.94 1.60 1.01
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1 week Blood 2.68 0.90 3.04 1.32
Heart 7.26 0.57 3.63 1.46
Lungs 15.06 6.05 15.60 11.14
Liver 45.97 9.28 54.28 14.13
Spleen 97.97 55.67 65.31 42.83
Testicles 4.35 0.87 2.50 0.56
Kidneys 15.11 1.35 9.20 4.16
Brain 2.56 0.39 2.24 0.30
4 weeks Blood 2.90 3.13 2.49 0.52
Heart 1.81 1.52 2.42 0.70
Lungs 16.87 6.32  10.70 4.73
Liver 11.03 5.83 39.29 10.16
Spleen 26.13 7.47 57.69  6.56
Testicles 1.74 0.77 2.39 0.36
Kidneys 4.20 1.50 7.38 1.39
  Brain   0.96 0.01 1.60 0.02      
Table 4.IV. Body distribution (in mg nanoparticles per g tissue weight) after intravenous administration of
14C-PBCA nanoparticles, polysorbate 80-coated  
14C-PBCA nanoparticles, and DOX  
14C-PBCA loaded
nanoparticles in healthy rats.
The brain is the most relevant organ for the polysorbate 80-coated nanoparticles since these
particles enabled an enhanced drug transport into this organ after intravenous injection
targeting (Kreuter 1983a, Alyautin et al. 1995, Kreuter et al. 1995, Schröder and Sabel
1996, Alyautin et al. 1997, 1998, Gulayev et al. 1999).  Therefore, most emphasis was put
on this organ in the present study. In brain, 
14C-PBCA nanoparticles, PS 80-coated 
14C-
PBCA nanoparticles, and DOX 
14C-PBCA nanoparticles showed similar concentrations 10
minutes after injection (Fig 4.6).
Precisely, the brain concentration of the mentioned formulations reached 0.2 % dose/gr
tissue. Enhanced brain concentrations of polysorbate 80-coated 
14C-PBCA nanoparticles
appeared after 1 hour and continued for the rest of the study. After 1 h the percentage of the
dose/gr tissue was increased by 0.80 % with the polysorbate 80-coated particles and by
0.30 % with the DOX 
14C-PBCA nanoparticles.
The amount in the blood was increased slightly (statistically not significant) after coating
with polysorbate 80 and at 10 min post injection even statistically significant after coating
with doxorubicin plus polysorbate 80.   These differences diminished after longer time
periods (Tables 4.III and 4.IV).
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Figure 4.6.  Biodistribution of nanoparticles (NP), nanoparticles + polysorbate 80 (PS), and doxorubicin-
loaded and polysorbate-80 coated nanoparticles (NP+PS+DOX)  in rat brain of healthy rats after  intravenous
administration of  20 mg/kg of nanoparticles.
In the organs of the reticulo endothelial system (RES), i.e. liver, spleen, lungs, the picture
was more complex. In general, polysorbate 80-coating reduced the liver and spleen
concentrations by about 40 to 50 %, but in some cases (1 h, 6 h, 3 days) increased the lung
concentrations. The addition of doxorubicin to these particles in general compensated the
effects of polysorbate 80-coating and resulted in similar RES organ concentrations as the
uncoated particles. 
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Figure 4.7. Biodistribution of nanoparticles (NP), nanoparticles + polysorbate 80 (PS), and doxorubicin-
loaded and polysorbate-80 coated nanoparticles (NP+PS+DOX) in main organs of healthy rats 1 h after
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intravenous administration of  20 mg/kg of nanoparticles.
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Figure 4.8. Biodistribution of nanoparticles (NP), nanoparticles + polysorbate 80 (PS), and doxorubicin-
loaded and polysorbate-80 coated nanoparticles (NP+PS+DOX) in main organs of rats, 24 h after intravenous
administration of  20 mg/kg of nanoparticles.
Similar fluctuations in concentrations were observed in the other organs investigated, i.e.
heart, kidneys, and testicles, and probably were caused by the biological variations. No
important or relevant concentration increases or decreases were caused by any of the three
preparations (Figs 4.7 and 4.8).
4.4.3 Tumour-bearing rats
4.4.3.1 Five days glioblastoma bearing rats
4.4.3.1.1 Body Distribution  
In rats to which the nanoparticles were injected i.v. 5 days after tumour-implantation, the
concentration of nanoparticles in the blood was decreased of 5 % dose after coating with
polysorbate 80 and binding with doxorubicin (Tables 4.V and 4.VI) at 10 minutes post
injection. After 1 hour and 6 h, DOX 
14C-PBCA nanoparticles displayed the lowest blood
concentration (7.3 % and 2.5 % of dose respectively).
Regarding the organs of the reticulo endothelial system (RES) i.e. liver, spleen, lungs, an
accumulation of particles was shown in those organs. The concentrations of the three
formulations in those organs were different: the coating with polysorbate 80 reduced the
uptake by the organs of the RES. The percent of dose of NP in the liver at 10 min post
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injection was 43 % whereas at the same time and in the same organ NP+PS 80 displayed a
reduced concentration of 19.5 % of the administered dose. The addition of doxorubicin to
the particles led to a concentration of 45 % of the dose. A comparable tendency was as well
shown at 1 h, 6 h, post injection.
In general the coating with the surfactant reduced the uptake and the adsorption of
doxorubicin neutralized the effect of polysorbate 80 of diminished uptake by the RES.
Concerning the concentrations of nanoparticles in the brain, PS 80-coated  
14C-PBCA
nanoparticles, and DOX  
14C-PBCA nanoparticles showed higher concentrations of  
14C-
PBCA nanoparticles, 10 minutes after injections (0.30, 0.31, 0.21 % of the dose/g tissue
respectively) (Fig 4.9). After 1 hour PS 80-coated 
14C-PBCA nanoparticles reached 0.37 %
of the dose/g tissue while  
14C-PBCA nanoparticles and DOX  
14C-PBCA nanoparticles
decreased the brain concentrations (0.13 %, 0.22 % dose/g tissue, respectively). However
these values were not statistically relevant. The nanoparticles brain concentration of all
three formulations diminished at extended times.
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Time Sample NP NP+PS 80 NP+PS 80+DOX
   
Percent
dose S.D. Percent
dose S.D. Percent
dose S.D.
10 min Blood 17.82 2.87 12.84 4.31 12.49 2.85
Heart 1.07 0.42 0.59 0.15 0.78 0.16
Lungs 11.16 2.99 7.79 4.87 8.18 1.73
Liver 43.27 1.44 19.50 7.46 44.83 5.95
Spleen 4.67 1.56 1.46 0.89 2.20 0.51
Testicles 1.06 0.36 0.54 0.09 0.73 0.11
Kidneys 7.39 4.43 4.61 1.02 8.36 2.19
Brain 0.35 0.17 0.50 0.17 0.51 0.11
1 h Blood 9.84 2.18 9.46 3.19 7.32 1.06
Heart 0.50 0.18 0.58 0.33 0.36 0.07
Lungs 2.25 0.73 6.89 1.02 4.66 1.35
Liver 33.85 9.20 22.20 12.10 28.66 3.97
Spleen 1.71 0.65 0.96 0.61 2.08 1.13
Testicles 0.71 0.13 0.72 0.36 0.63 0.05
Kidneys 3.22 0.58 3.31 1.35 2.65 0.68
Brain 0.24 0.23 0.64 0.32 0.38 0.04
6 h Blood 4.41 0.78 4.01 0.84 2.52 1.05
Heart 0.24 0.04 0.65 0.81 0.18 0.02
Lungs 1.11 0.28 5.21 0.58 2.11 0.43
Liver 17.80 3.94 15.33 2.48 27.14 1.48
Spleen 1.23 0.52 2.91 3.66 1.64 0.59
Testicles 0.51 0.24 0.22 0.04 0.29 0.04
Kidneys 1.06 0.24 1.20 0.19 1.20 0.14
Brain 0.14 0.04 0.13 0.02 0.24 0.03
24 h Blood 1.69 0.20 1.49 0.48 2.04 0.62
Heart 0.15 0.07 0.15 0.14 0.15 0.04
Lungs 0.55 0.27 2.57 0.51 0.96 0.43
Liver 12.42 4.10 13.09 1.18 21.10 3.16
Spleen 1.19 0.34 1.02 0.20 1.20 0.35
Testicles 0.18 0.04 0.15 0.02 0.22 0.05
Kidneys 0.71 0.29 0.59 0.20 0.85 0.04
  Brain 0.03 0.01 0.05 0.03 0.09 0.02
Table 4.V. Body distribution of 
14C as percent of the dose after intravenous administration 5 days after
tumour transplantation of 
14C-PBCA nanoparticles, polysorbate 80-coated 
14C-PBCA nanoparticles, and DOX
14C-PBCA loaded nanoparticles. 
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Time Sample NP NP+PS 80  NP+PS 80+DOX
µg 
NP/g S.D. µg 
NP/g S.D. µg 
NP/g S.D.
10 min Blood 80.84 13.03 58.26 19.53 57.46 8.88
Heart 50.21 25.42 35.71 8.91 40.23 1.46
Lungs 405.05 108.34 317.53 157.91 350.08 103.57
Liver 214.11 7.13 101.3 36.91 233.87 45.81
Spleen 358.90 70.16 159.20 96.51 220.93 88.62
Testicles 22.99 7.76 11.79 2.02 18.05 1.44
Kidneys 211.75 126.98 132.13 29.22 262.96 14.71
Brain 17.49 5.36 19.08 5.53 23.40 3.41
1 h  Blood 44.63 9.90 42.93 14.48 33.20 4.80
Heart 30.53 10.76 35.00 20.03 22.00 4.02
Lungs 81.61 26.51 250.12 37.01 168.95 49.10
Liver 167.48 45.52 109.82 59.85 141.83 19.64
Spleen 185.96 70.90 104.00 66.50 226.55 122.85
Kidneys 92.18 16.53 94.81 38.71 75.81 19.59
Brain 13.35 7.27 40.44 10.18 25.15 1.41
6 h Blood 20.01 3.56 18.21 3.79 11.43 4.76
Heart 14.22 2.19 39.37 48.95 11.18 0.91
Lungs 40.17 10.01 188.96 21.02 80.56 15.68
Liver 88.05 19.48 75.87 12.27 134.27 7.32
Spleen 101.39 56.67 200.95 19.77 139.70 64.68
Testicles 4.21 5.22 1.82 0.95 1.92 0.91
Kidneys 30.30 6.93 34.47 5.55 34.48 3.89
Brain 8.74 1.33 7.09 0.77 10.61 1.00
24 h Blood 7.67 0.92 6.76 2.18 9.24 2.79
Heart 9.04 4.48 8.92 8.22 9.15 2.43
Lungs 19.94 9.68 93.30 18.39 34.83 15.74
Liver 61.47 20.30 64.78 5.85 104.40 15.65
Spleen 129.08 36.64 111.44 22.22 130.35 37.79
Testicles 3.91 0.87 3.27 0.52 4.79 0.99
Kidneys 16.30 8.18 20.76 5.70 24.46 1.04
  Brain 3.20 0.29 3.96 0.80 4.64 0.77
Table 4.VI. Body distribution (in mg nanoparticles per g tissue weight) after intravenous administration 5 days
after tumour transplantation of 
14C-PBCA nanoparticles, polysorbate 80-coated 
14C-PBCA nanoparticles, and
DOX 
14C-PBCA loaded nanoparticles. 
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Figure 4.9  Brain  distribution  after intravenous administration  of  20  mg/kg  
14C-PBCA nanoparticles,
polysorbate 80-coated  
14C-PBCA nanoparticles, and DOX  
14C-PBCA loaded nanoparticles 5 days after
tumour transplantation. 
4.4.3.1.2 Nanoparticle concentrations in glioblastoma  
Fig. 4.10 shows the concentration of nanoparticles in glioblastoma 101/8, the principal
target of the nanoparticles of the present study. 
The most prominent results was the relative high concentration reached by DOX 
14C-PBCA
nanoparticles after 1 h and 6 h (0.68 % and 0.51 % dose/g tissue). However the small
tumoural mass 5 days after the tumour implantation limited the reliability of the data
presented.  
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Figure 4.10. Concentration of nanoparticles (NP), nanoparticles + polysorbate 80 (PS), and doxorubicin-
loaded and polysorbate-80 coated nanoparticles (NP+PS+DOX) in glioblastoma after i.v. injection of 20 mg/
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kg nanoparticles 5 days after tumour transplantation.
4.4.3.2 Eight days glioblastoma bearing rats
4.4.3.2.1 Body distribution  
In the rats that obtained the nanoparticle formulations 8 days after tumour transplantation,
the coating of nanoparticles with PS 80 led to a significant increase of NP concentration in
the blood 10 min after nanoparticle injection. As Tables 4.VIII and 4.IX show, the blood
NP+PS 80 concentration was of 22 % of the injected dose and 29 % of the dose for NP+PS
80+DOX. The blood concentration of uncoated and unloaded NP after 10 min was only 5.4
% of the dose/ g. After 1 h the differences in blood concentration for all three formulations
were diminished. The particles blood concentration was not significant at 6 h and 24 h post
injection. 
An important accumulation of particles was shown in the liver (Tables 4.VIII and 4.IX)
being the major organ of the RES. At 10 min post injection NP+PS 80 reached the
concentration of 34 % of the dose while the uncoated NP concentration was 17 % of the
dose. The liver concentration observed after DOX binding was 20 % of the dose.  
After 1 h NP+PS 80+DOX achieved a liver concentration of 30 % of the dose whereas NP,
and NP+PS 80 achieved in the liver the concentration of 21 % and 26 % of the dose,
respectively.  
Noteworthy was the liver accumulation of coated nanoparticles (NP+PS 80 and NP+PS
80+DOX) at 6 h post injection.
Regarding  the  particles  concentration  in the spleen,  no important differences  were
displayed 10 min after injection between the three formulations. At 1 h the spleen
concentration of NP and NP+PS 80+DOX were about two-fold higher than that of NP+PS
80.
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Time Sample NP NP+PS 80 NP+PS 80+DOX
   
Percent
dose S.D. Percent
dose S.D. Percent
dose S.D.
10 min Blood 5.36 1.58 21.65 5.78 28.63 10.13
Heart 0.45 0.49 1.02 0.22 1.51 0.62
Lungs 2.59 2.05 7.06 4.44 5.28 3.27
Liver 16.80 9.14 33.73 3.73 20.26 7.86
Spleen 0.95 0.73 1.15 0.37 0.99 0.29
Testicles 0.30 0.12 0.96 0.22 1.21 0.49
Kidneys 1.78 0.80 8.15 2.20 8.58 0.74
Brain 0.37 0.11 0.55 0.18 0.58 0.26
1 h Blood 4.34 0.59 9.57 1.06 8.32 1.74
Heart 0.22 0.03 0.51 0.16 0.49 0.17
Lungs 11.55 8.76 3.08 0.59 8.73 2.10
Liver 21.37 3.45 26.34 1.99 30.41 4.28
Spleen 1.46 0.27 0.76 0.06 1.69 0.61
Testicles 0.44 0.19 0.63 0.09 0.66 0.14
Kidneys 1.51 0.52 3.45 0.65 4.52 2.86
Brain 0.26 0.08 0.57 0.06 0.67 0.37
6 h Blood 0.21 0.02 0.48 0.15 2.52 1.05
Heart 0.01 0.00 0.02 0.01 0.18 0.02
Lungs 0.12 0.02 0.55 0.21 2.11 0.43
Liver 19.74 0.09 23.75 0.60 27.14 1.48
Spleen 0.07 0.02 0.11 0.04 1.64 0.59
Testicles 0.01 0.00 0.03 0.01 0.29 0.04
Kidneys 0.06 0.02 0.13 0.06 1.20 0.14
Brain 0.11 0.00 0.12 0.00 0.24 0.03
24 h Blood 0.46 0.02 1.93 0.31 1.77 0.29
Heart 0.03 0.01 0.14 0.05 0.17 0.04
Lungs 0.46 0.34 0.80 0.13 1.80 0.34
Liver 3.97 1.50 14.00 2.28 19.43 2.85
Spleen 0.43 0.25 0.56 0.15 1.30 0.44
Testicles 0.04 0.02 0.19 0.03 0.24 0.04
Kidneys 0.15 0.05 0.71 0.07 0.86 0.19
  Brain 0.02 0.00 0.11 0.02 0.17 0.05
Table 4.VIII. Body distribution of 
14C as percent of the dose after intravenous administration  8 days after
tumour transplantation of 
14C-PBCA nanoparticles, polysorbate 80-coated 
14C-PBCA nanoparticles, and DOX
14C-PBCA loaded nanoparticles.
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Time Sample NP NP+PS 80 NP+PS 80+DOX
µg 
NP/g S.D. µg 
NP/g S.D. µg 
NP/g S.D.
10 min Blood 24.29 7.15 84.55 8.44 104.86 83.06
Heart 17.02 6.21 57.65 12.30 73.28 61.62
Lungs 121.92 63.34 270.75 105.73 210.47 76.74
Liver 83.14 45.25 160.24 16.19 105.11 38.89
Spleen 107.80 67.53 132.22 24.81 115.78 50.59
Testicles 6.42 2.53 18.69 2.30 21.34 17.52
Kidneys 50.99 22.95 200.54 47.95 217.82 131.35
Brain 13.76 3.38 22.84 1.84 29.20 12.97
1 h  Blood 19.68 2.65 42.33 5.16 39.25 8.72
Heart 13.30 1.77 31.35  10.68 29.73 11.48
Lungs 319.46 45.25 68.95 15.09 251.98 89.66
Liver 105.72 17.08 128.42 9.98 148.37 24.14
Spleen 158.39 29.04 79.83 4.55 176.35 76.50
Testicles 9.50 4.08 13.50 1.82 14.80 3.49
Kidneys 43.11 14.82 97.02 21.75 151.06 83.59
Brain 8.20 2.63 18.89 2.23 30.95 13.43
6 h Blood 0.97 0.08 2.07 0.78 8.63 7.86
Heart 0.60 0.00 1.21 0.38 7.15 5.55
Lungs 4.31 0.66 19.23 8.16 49.23 40.97
Liver 96.99 13.46 117.49 30.31 135.74 55.15
Spleen 7.62 1.93 9.98 3.80 135.33 117.28
Testicles 0.24 0.08 0.65 0.19 3.91 3.08
Kidneys 1.58 0.61 3.53 1.90 21.33 16.53
Brain 2.32 0.00 2.53 0.17 4.73 3.69
24 h Blood 2.08 0.08 9.03 1.49 8.10 1.56
Heart 1.61 0.31 8.57 3.12 10.48 2.47
Lungs 16.51 12.20 31.14 2.82 66.16 13.75
Liver 19.66 7.44 74.66 5.28 93.97 15.98
Spleen 46.63 27.69 66.95 14.58 138.43 55.80
Testicles 0.83 0.35 4.17 0.73 5.01 0.79
Kidneys 4.34 1.54 20.53 1.99 24.40 6.39
  Brain 0.24 0.00 3.74 0.69 5.23 4.82
Table 4.IX. Body distribution (in mg nanoparticles per g tissue weight) after intravenous administration 8 days
after tumour transplantation of 
14C-PBCA nanoparticles, polysorbate 80-coated 
14C-PBCA nanoparticles, and
DOX 
14C-PBCA loaded nanoparticles. 
- 78 -Results
0,00
0,20
0,40
0,60
0,80
1,00
10 min 1 h 6 h 24 h
%
 
D
o
s
e
/
 
g
 
t
i
s
s
u
e
 
NP
NP+PS
NP+PS+DOX
Figure 4.11. Brain distribution after intravenous administration of 20 mg/kg 14C-PBCA nanoparticles,
polysorbate 80-coated 14C-PBCA nanoparticles, and DOX 14C-PBCA loaded nanoparticles 8 days after
tumour transplantation. 
Regarding the brain distribution, nanoparticles without coating showed the lowest brain
concentration (Figure 4.11). The coating with polysorbate 80 enhanced the brain up-taking.
Finally doxorubicin nanoparticles reached the highest concentration at each time point.
4.4.3.2.2 Nanoparticles concentration in glioblastoma  
A concentration of almost 1 % of the dose/g tissue was obtained by DOX 
14C-PBCA
nanoparticles after 10 min post injection (Fig 4.12). 
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Figure 4.12. Concentration of nanoparticles (NP), nanoparticles + polysorbate 80 (PS), and doxorubicin-
loaded and polysorbate-80 coated nanoparticles (NP+PS+DOX) in glioblastoma after i.v. injection of 20
mg/kg nanoparticles 8 days after tumour transplantation.
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The concentration of these particles was reduced to 0.58 % after 1 h. The other
nanoparticle preparations yielded lower concentrations in the glioblastoma, except the 
14C-
PBCA  PS 80-coated NP, which reached the concentration of 0.62 % of the dose/ g tissue
after 1 h. However this value was not statistically significant.  
4.4.3.3 Ten days glioblastoma bearing-rats
4.4.3.3.1 Body Distribution  
The body distribution of [
14C]-PBCA NP in tumour bearing rats 10 days post tumour
implantation is shown in Table 4.X (percent of dose) and Table 4.XI (µg/g tissue weight).
The blood concentrations 10 min and 1 h post injection were comparable for the three
formulations. After 10 min, doxorubicin loaded nanoparticles showed a slightly higher
concentration in comparison with NP and NP+PS 80 (15 % versus 11 %, and 9 % of the
dose, respectively) (Table 4.X). A similar tendency was observed 1 h and 6 h after
injection.
In the organs of the reticuloendothelial system (RES), i.e. liver, spleen, and lungs, the
biodistribution pattern was more complex. Polysorbate 80-coating reduced the liver and
spleen concentrations of the unloaded particles. In fact, 10 min after injection the liver
concentration of NP was ~35 %, whereas the concentration of NP+PS 80 was reduced to
~24 %. The same tendency was displayed at 1 h and 6 h after injection. The concentration
of coated and uncoated [
14C]-PBCA NP at 24 h post injection in liver and spleen was
comparable.
The behaviour of doxorubicin-loaded [
14C]-PBCA NP was different. Although those
particles were coated with PS 80, the addition of doxorubicin seemed to abolish the effect
of the coating, which resulted in similar or even higher RES organ concentrations, as
compared to the uncoated particles. 
Investigation of other organs, such as heart, kidneys, and testicles did not reveal any
important difference between the three preparations.
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Time Sample NP NP+PS 80 NP+PS 80+DOX
Percent
dose S.D. Percent
dose S.D. Percent
dose S.D.
10 min Blood 11.49* 2.55 9.12* 0.76 15.24* 2.16
Heart 0.82* 0.17 0.56* 0.13 0.75* 0.08
Lungs 3.63 0.92 8.11 4.73 11.93 9.56
Liver 34.76* 3.49 24.32* 8.62 36.82* 3.40
Spleen 2.81 0.89 1.54 0.82 4.59 0.57
Testicles 0.88 0.15 0.58 0.26 0.94 0.39
Kidneys 5.68* 0.15 3.72* 1.59 8.56 2.36
Brain 0.49* 0.15 0.59* 0.06 0.56* 0.08
1 h Blood 7.94* 1.48 6.19* 0.56 9.16* 1.72
Heart 0.31* 0.08 0.31* 0.03 0.52* 0.02
Lungs 1.54 0.32 5.46 0.78 5.29 0.88
Liver 24.41 6.29 18.44* 1.06 36.69* 1.82
Spleen 1.67 0.65 1.24 0.23 1.50 0.17
Testicles 0.66 0.18 0.44* 0.04 0.71* 0.06
Kidneys 2.21 0.61 2.25* 0.31 4.10* 0.05
Brain 0.49* 0.02 0.76* 0.08 0.93* 0.04
6 h Blood 2.30 0.28 2.56 0.13 4.43 0.73
Heart 0.11* 0.01 0.16* 0.01 0.27 0.09
Lungs 0.64 0.09 2.79 0.97 2.73 0.53
Liver 14.64* 1.49 10.96* 2.36 20.93* 2.11
Spleen 1.00 0.11 0.89 0.65 0.93 0.13
Testicles 0.18* 0.03 0.19* 0.05 0.32* 0.08
Kidneys 0.58 0.08 0.71 0.14 1.29 0.35
Brain 0.11* 0.03 0.14* 0.04 0.25* 0.05
24 h Blood 1.07 0.17 1.28 0.27 1.88 0.30
Heart 0.08 0.02 0.10 0.04 0.14 0.04
Lungs 0.29 0.06 0.80* 0.08 7.69* 0.54
Liver 10.52* 1.41 11.60* 1.00 18.96* 2.67
Spleen 0.85 0.20 0.87 0.19 1.23 0.21
Testicles 0.10* 0.02 0.12* 0.03 0.17* 0.04
Kidneys 0.36* 0.05 0.47* 0.04 0.85 0.10
Brain 0.05* 0.01 0.07* 0.02 0.10* 0.03
* difference in mean values statistical significant (P < 0,05)
Table 4.X. Body distribution of 
14C as percent of the dose after intravenous administration 10 days after
tumour transplantation of 
14C-PBCA nanoparticles, polysorbate 80-coated 
14C-PBCA nanoparticles, and DOX
14C-PBCA loaded nanoparticles.
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Time Sample NP NP+PS 80 NP+PS 80+DOX
µg 
NP/g S.D. µg 
NP/g S.D. µg 
NP/g S.D.
10 min Blood 52.10* 11.57 42.12* 3.71 70.98* 10.75
Heart 49.29* 10.49 36.99* 6.15 46.67* 4.90
Lungs 131.59 33.23 203.92 35.71 251.28 101.27
Liver 171.97* 17.25 129.37* 46.34 186.59* 17.28
Spleen 305.52 96.70 177.62 102.76 620.30 77.97
Testicles 19.05 3.36 14.26 5.80 21.73 9.51
Kidneys 162.71 47.52 114.35 50.96 229.27 71.91
Brain 15.96* 4.84 19.03* 2.39 18.34* 3.11
1 h  Blood 36.03* 6.70 28.09* 2.52 41.52* 7.81
Heart 18.82* 4.69 18.90* 1.61 31.30* 1.43
Lungs 55.83 11.44 198.07 28.31 191.77 31.83
Liver 120.78 31.11 91.25* 5.23 181.53* 8.99
Spleen 181.93 70.39 134.85 24.62 163.12 18.07
Testicles 14.37 4.02 9.47* 0.88 15.40* 1.22
Kidneys 63.16* 17.56 64.49* 9.02 117.52* 1.43
Brain 16.03* 0.78 24.65* 2.28 30.37* 1.29
6 h Blood 10.42 1.28 11.60 0.61 20.10 3.31
Heart 6.73* 0.75 9.45* 0.72 16.33 5.20
Lungs 23.09 3.09 101.19 35.08 99.12 19.11
Liver 72.41* 7.37 54.25* 10.41 103.54* 10.46
Spleen 108.58 12.39 96.63 71.30 100.98 13.89
Testicles 3.97* 0.67 4.14* 1.00 7.00* 1.64
Kidneys 16.69 2.30 20.20 3.87 36.86 10.12
Brain 3.60* 0.83 4.44* 1.27 8.11* 1.56
24 h Blood 4.87 0.77 5.82 1.21 8.50 1.36
Heart 4.99 0.96 5.97 2.34 8.32 2.16
Lungs 10.48 2.14 29.12* 2.73 279.12* 78.92
Liver 52.03* 6.99 57.42* 4.97 93.82* 13.19
Spleen 91.98 22.00 94.14 20.24 133.76 23.27
Testicles 2.26* 0.38 2.64* 0.55 3.67* 0.84
Kidneys 10.42* 1.43 13.39* 1.26 24.31 2.83
  Brain 1.76* 0.24 2.52* 0.58 3.48* 0.81
* difference in mean values statistical significant (P < 0,05)
Table 4.XI. Body distribution (in mg nanoparticles per g tissue weight) after intravenous administration 10
days after tumour transplantation of 
14C-PBCA nanoparticles, polysorbate 80-coated 
14C-PBCA nanoparticles,
and DOX 
14C-PBCA loaded nanoparticles. 
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In brain, 
14C-PBCA nanoparticles, PS 80-coated 
14C-PBCA nanoparticles, and DOX 
14C-
PBCA nanoparticles showed similar concentrations 10 minutes after injection (Fig. 4.13).
Precisely, the brain concentration of the mentioned formulations reached about 0.3-0.35 %
of the dose/ g tissue. Enhanced brain concentrations of polysorbate 80-coated 
14C-PBCA
nanoparticles appeared after 1 hour. After 1 h the percentage of the dose/ g tissue was
increased to 0.45 % with the polysorbate 80-coated particles and to 0.57 % with the DOX
14C-PBCA nanoparticles. After 6 h the brain concentration of all three formulations was
significantly decreased. The concentration of DOX  
14C-PBCA nanoparticles was still
higher than that of the 
14C-PBCA nanoparticles and PS 80-coated 
14C-PBCA nanoparticles.
Noteworthy is the increase of the NP brain concentration for all formulations from day 5 to
day 10, although in most cases this difference was not statistically significant. The highest
concentration (statistically significant) was reached using doxorubicin-loaded [
14C]-PBCA
NP 1 h post injection in 10 days tumour bearing rats (0.93 %, Tab 4.X).
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Figure 4.13. Brain distribution after intravenous administration of 20mg/kg of  
14C-PBCA nanoparticles,
polysorbate 80-coated  
14C-PBCA nanoparticles, and DOX  
14C-PBCA loaded nanoparticles 10 days after
tumour transplantation. 
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4.4.3.3.2 Nanoparticles concentration in glioblastomas  
Ten days post tumour implantation the glioblastomas reached the size range of 2 - 5 mm.
The concentration of DOX 
14C-PBCA nanoparticles reached a remarkable 2.4 % of the
dose/g tissue at 10 min post injection (Figure 4.14). However this value was not
statistically significant compared to the other two formulations.
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Figure 4.14. Concentration of nanoparticles (NP), nanoparticles + polysorbate 80 (PS), and doxorubicin-
loaded and polysorbate-80 coated nanoparticles (NP+PS+DOX) in glioblastoma after i.v. injection of 20
mg/kg nanoparticles 10 days after tumour transplantation.
After 1 h PS 80-coated [
14C]-PBCA nanoparticles reached a concentration of 0.9 % dose/g
tissue. This value is two-fold of the concentration of  
14C-PBCA nanoparticles in the
surrounding brain tissue (Figure 4.13). The three formulations maintained a similar
concentration (between 0.3 - 0.4 % dose/g tissue) at 6 h and 24 h post injection,  and at
each time point the nanoparticles tumour concentration is higher than brain concentration.
Figure 4.15 shows the percent of the injected dose per g tumour tissue for the three
formulations at 1 h post injection in the controlateral hemisphere and in the glioblastoma.
The figure is particularly representative for comparing the enhancement of the nanoparticle
formulations in the glioblastoma which was more pronounced than in the controlateral
hemisphere. Moreover the values were statistically significant (P < 0.05).
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Figure 4.15. Biodistribution of nanoparticles (NP), nanoparticles + polysorbate 80 (PS 80) and doxorubicin-
loaded and polysorbate 80 coated nanoparticles (NP+PS 80+DOX), in the brain of tumour-bearing rats, 1 h
after intravenous administration of  20 mg/kg of nanoparticles.
Significant extravasation into the glioblastoma was found for unloaded polysorbate 80-
coated [
14C]-PBCA NP whereas the concentration of other formulations was ~ 0.60 %.
For all formulations, [
14C]-PBCA NP concentration was slightly higher in the glioblastoma
than in the controlateral hemisphere.
4.4.4 Evaluation of the BBB integrity
Evans Blue has been commonly used to demonstrate a defective BBB in transplanted
rodent tumours (Ji et al. 1996, Prabhu et al. 2000).  
It could be seen that the accumulation of Evans Blue in the tumour remained low for 5 days
post tumour implantation (Fig 4.16). BBB disruption became pronounced on day 6 after
tumour implantation. Fluorescence in the contralateral hemisphere remained low within the
period of observation. The decrease of tumour fluorescence on day 9 may be due to a lower
penetration of the dye into the tumour tissue due poor vascularization of the tumour core
and necrosis occurring during the later stages of tumour development. 
.
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Figure   4.16.
Fluorescence of Evans
Blue   in   the   tumour
tissue and normal brain
tissue (contralateral hemisphere) at different stages of glioblastoma development (n = 3).
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4.5 Whole-body autoradiography (WBA) studies
 4.5.1 Body distribution of [14-
14C] DOX PBCA NP coated with PS 80 at 1 h, 2 h, 4 h
post injection
Figure 4.17 shows the body distribution of the PS 80-[14-
14C] DOX PBCA nanoparticles
two hours after intravenous injection into the tail vein of a rat. A high activity in the GI-
tract occurred due to the faecal elimination of PS 80-[14-
14C] DOX PBCA NP (Löbenberg
et al. 1998). An accumulation of nanoparticles was also visible in the organ of RES and in
the hearth. The results are in accordance with the liquid scintillation study. The body
distribution of PS 80-[14-
14C]  DOX PBCA NP at 1 h and 4 h post injection was
comparable (data not shown).
Figure 4.17. Radioluminography of a rat 2 h after i.v. injection of PS 80-[14-
14C] DOX PBCA NP.
4.5.2 Body distribution of PS 80-[14-
14C] DOX solution at 2 h post injection.
Figure 4.18 shows that PS 80-[14-
14C] DOX solution is relative homogeneously distributed
in all the cell of most organs. 
An important and significant difference between nanoparticles and solution was observed
in the liver. The comparison of the autoradiographs (Figs 4.17 and 4.18) after i.v. injection
of the two formulations showed a lower concentration of PS 80-[14-
14C] DOX PBCA NP
in the liver in comparison to the PS 80-[14-
14C] DOX solution.
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Fig 4.18. Radioluminography of a rat 2 h after i.v. injection of PS 80-[14-
14C] DOX control solution.
4.5.3 Brain distribution
Figure 4.19. Radioluminography of the brain of a rat 2 h after i.v. injection of PS 80-[14-
14C] DOX PBCA
NP.
The results of the brain distribution were similar for all the four rats. Therefore only the
radioluminography of one experiment  is illustrated (Fig 4.19). The concentrations in the
- 88 -Results
liquor and in the pineal body were considerable whereas no activity was observed in the
brain.
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5 Discussion  
5.1 Optimisation of nanoparticles formulation
The first part of the present study was focused on the development of a doxorubicin
nanoparticles formulation with an improved drug binding. The study was based on the
presumption that particles with higher drug loading could transport a higher quantity of the
drug into the brain, thus enhancing the therapeutic drug effect.
5.1.1 Influence of parameters on drug loading
The variations of parameters for nanoparticles preparation influenced the drug loading to a
different extent. The parameters investigated in the present study were: 1) concentration
and type of steric stabilizer; 2) monomer concentration and type of monomer; 3) pH of the
medium; 4) polymerization time. The influence of the latter parameters on nanoparticle
features can be described as following:
5.1.1.1 Influence of steric stabilizer
Doxorubicin nanoparticles were prepared at different concentration of dextran 70 000, used
as steric stabilizer. Drug loading was increased of ~ 5 % using the concentration of 2 %
dextran instead of 1 % (Tab 4.I).  
The effect of dextran concentration can be explained according to the theory of particle
formation   in   dispersion   polymerization   (Douglas   et   al.   1985,   Barret   et   al.   1975).
Nanoparticles formation is believed to occur via a nucleation mechanism. Initiation of
polymerization results in the formation of oligomeric chains which grow in solution until
they reach a critical molecular weight which depends on the solubility of the oligomer in
the medium. The chains then either collapse upon themselves producing particle nuclei or
several growing oligomeric chains may associate with each other to form an aggregate
which, above a certain critical size, precipitates forming a new stable nucleus. In either
case these nuclei can grow by capture of further oligomers from the solution. The stability
of the resultant colloidal system is achieved by adsorption of polymeric stabilizer, i.e.,
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dextrans. 
The initial high number of particle nuclei and their small particle size result in a very large
total particle surface area. At low dextran concentration the amount of stabilizer is
insufficient to effectively cover the available surface, resulting in a unstable colloidal
system. The smaller particles therefore agglomerate until the total particles surface area has
decreased to a point such that the amount of dextran available is sufficient to produce a
stable suspension.
At increased dextran concentration it is possible to stabilize a larger total particle surface
area, resulting in the formation of stable particles of a lower size. If the total particles
surface area is larger, a larger surface is available for binding doxorubicin molecules. The
consequence is that the total amount of drug bound to the particles is increased as well as
the drug loading. 
  
5.1.1.2 Influence of monomer concentration
The concentration of n-BCA was investigated in the range of 0.5 % w/v to 1 % w/v. A
decrease in monomer concentration to 0.75 % resulted in a progressive increase of
entrapment efficiency. Nevetheless with a further reduction of the monomer concentration
the drug loading decreased again. Although the monomer concentration is a factor
contributing to the particles size and consequently to the drug loading, the pattern is
complex and limited by the importance of a low polydispersity index and a maximum solid
content for a free flowing suspension. Indeed at a low monomer concentration below 1 %
(v/v) the polydispersity was found to be high, but decreased rapidly with increasing
monomer concentration (Douglas et al. 1984).     
5.1.1.3 Influence of pH medium
A pH of 2 was optimal for obtaining a significant value of drug loading (Tab 4.I).  A
deviation from this pH reduced the drug loading substantially.  
This   result   can  be   explain   by  reference   to   the   polymerization   reaction   (Fig  2.6).
Polymerization occurs via an anionic mechanism involving initiation by nucleophilic attack
on the b-carbon of butyl-2-cyanoacrilate. The resulting carbanion produced reacts with
further monomers to form oligomeric chains which nucleate leading to the formation of
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nanoparticles. The major initiating nucleophile is OH
-, the concentration of which varies
with pH. At high pH and hence high hydroxyl ion concentration, the polymerization rate is
too rapid to allow discrete particle formation and leads to direct polymerization of
monomer droplets producing an amorphous polymer mass. As pH decreases the decrease in
reaction rate allows nanoparticles formation to occur. However, if the pH is too low the
polymerization period is greatly extended and nanoparticles in this system become swollen
with monomer. Coagulation of these semi-fluid particles is not reversible and so produces
a polydispersed system of larger particles and larger specific surface area on which
molecules of drug can bound. Hence a minimum size and higher loading are observed in
the pH profile when polymerization is slow enough to give discrete particles but not so
slow as to allow excessive particle coagulation (Douglas et al. 1985).
5.1.1.3 Influence of polymerization time
The prolongation of polymerization time up to 4 h led to an increase of 4 % in entrapment
efficiency of nanoparticles prepared with 0.75 % monomer and 2 % dextran. This may be
attributed to the high monomer to polymer conversion with time, leading to an increase on
the amount of the polymer formed, thereby incorporating a larger amount of drug (Reddy
and Murthy 2004).
5.1.1.4 Influence of dextran 70 000 and poloxamer 188 (Pluronic
Ò F 68)
The employment of poloxamer 188 as steric stabilizer instead of dextran significantly
reduced the quantity of doxorubicin bounded to the particles (~ 30 % of loading less using
poloxamer 188), although lower polydispersity and particle sizes are gained by the use of
poloxamer 188. To explain this behavior it was necessary investigate the zeta potenzial of
nanoparticles stabilized with dextran and poloxamer 188.    
It was found out that the zeta potential was  –14 mV for dextran nanoparticles and  –3.2
mV for  poloxamer 188 nanoparticles. 
These differences also can be explained on the basis of previous reports. Douglas et al.
(1985) reported the presence of residual amounts of dextran in cyanoacrylate nanoparticles
in the bulk as well as at the surface. A similar observation was reported by Edman et al.
(1980) in the development of polyacryl dextran biodegradable microparticles. High zeta
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potential values observed for the nanoparticles prepared using dextran were attributed to
the contribution of charge by dextran 70 000 (dextran-O
-), adsorbed onto the nanoparticle
surface. This is not the case for nanoparticles prepared in the presence of the nonionic
surfactant poloxamer 188. The nanoparticles stabilized by poloxamer 188 were surfactant
stabilized during the polymerization, and hence the possibility of a masking effect on
particle charge due to surfactant adsorption cannot be ruled out. Such a decrease in zeta
potential after coating with block copolymers also was observed by Hawley et al. (1997)
with   poly(DL-lactide-co-glycolide)   nanospheres.   Incorporation   of   doxorubicin   into
nanoparticles showed a decrease in zeta potential values in both of the above cases, the
decrease being high in dextran nanoparticles (+0.1 mV nanoparticles prepared with
poloxamer 188 and +2 mV for particles prepared with dextran). The positive charge due to
the doxorubicin on the nanoparticles surface can be attributed to the daunosamine sugar
moieties.   During   the   polymerization   process,   adsorption   of   doxorubicin   onto   the
nanoparticle surface is possible, contributing to masking the polymer charge. A significant
decrease in the zeta potential of doxorubicin nanoparticles prepared with dextran in
comparison to those prepared with poloxamer 188, further strengthens the aspect of
dextran presence on the particle surface, whose charge is masked by the adsorbed drug,
contributing to the overall great decrease of the zeta potential.
The significant change of the zeta-potential in DOX nanoparticles prepared with dextran
suggests that strong electrostatic interactions occur between doxorubicin and the negative
particle surface, and this phenomenon explains the high entrapment efficacy. Oppositely,
the slight variation of zeta potenzial after loading with doxorubicin to particles prepared
with poloxamers 188 indicates that the electrostatic interactions are weak, and this aspect
affects the drug loading that is significantly decreased.
5.1.1.5 Influence of n-butyl-2- cyanoacrylate and iso-butyl-2-cyanoacrylate 
Iso-butyl-2-cyanoacrylate is an isomer of n-butyl-2-cyanoacrylate in which the butyl lateral
chain is branched. The doxorubicin loading of iso-PBCA nanoparticles is 5 % higher than
n-PBCA. The rationale for the increase of drug entrapment efficacy can be addict to
lipophilic interactions between doxorubicin and the polymer. The presence of a branched
lateral chain allows extended hydrophobic interaction. The two methyl groups of the iso-
BCA enhance the anchorage of doxorubicin by hydrophobic interactions. The lipophilic
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anthracycline part is involves in those bounds.
5.2 Release studies 
5.2.1 Release with dialysis  tube
 
The release study carried out with dialysis tube exhibited for all the formulations a biphasic
pattern (Fig 4.1). The biphasic pattern of doxorubicin solution suggested that this method is
not fully revealing the actual release dynamics. The curve relative to DOX solution
evidenced that doxorubicin molecules require time to cross the dialysis membrane.
Therefore, the curves result from the release of the drug from the particles and plus the
time for crossing the membrane. Another limitation of this method was the adsorption of
doxorubicin to the dialysis membrane. Almost 30 % of the drug was absorbed 500 min
after beginning of the diffusion process.
Despite these limitations, assumptions on the release mechanism of doxorubicin from
nanoparticles can be formulated. The release profile of doxorubicin from nanoparticles
may be described using a biexponential function:
Ct = Ae
-at + Be
-bt
where Ct  is the concentration of compound remaining in the nanoparticles at time t, A and
B are system-charachteristic constants, and a and b are rate constants that can be obtained
from semilogathmic plots (Illum et al 1986b). 
The initial release rate was faster. The rapid release was due to the desorption of the drug
from the particles surface. This adsorbed drug has little value in drug targeting as it is
rapidly removed from the particle surface upon intra-arterial administration (Pramod et al.
1986). 
The release of the remaining drug was slow due to the process of diffusion of the drug
through the nanoparticles matrix. Thus the release profile suggests that doxorubicin carried
by nanoparticles was associated with PBCA nanoparticles either by adsorption onto the
particle surface or by inclusion in the nanoparticles matrix. 
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5.2.2 Release with centrifuge filters and with microtubes
The  curves   (Figs   4.2  and  4.3)   show  that   almost   all   the  drug  was   released   after
nanoparticles centrifugation. The g-force squeezed the nanoparticles and caused the
immediate desorption of doxorubicin from the particles.  
5.2.3 Interactions between doxorubicin and poly(butyl cyanoacrylate) nanoparticles
The studies of doxorubicin release from the particles present difficulties due to the
weakness of the bonds between the drug and the PBCA matrix that led to the immediate
release of doxorubicin.
The release of the adsorbed drug depends mainly on the affinity of the drug to the particles
surface. The interaction between DOX and the oligomeric poly(alkyl cyanoacrylate) in
nanoparticles was studies computationally by Poupaert and Couvreur (2003). The cohesion
of drug and particles comes from a blend of dipole-charge interaction, H bonds, and
hydrophobic forces. The dipole-charge interaction represents the main stabilizing factor for
the complex. Nitrile groups from PBCA were the main actors in this scenario being in
close interaction with the ammonium moiety present in the protonated amminosugar
moiety  of   doxorubicin.   The   protonation   of   the   N(3)   amminosugar   moiety  of   the
doxorubicin occurs at physiological pH  and this positive group has a significant influence
on the molecular recognition for doxorubicin binding.
Calculation of the zeta potential reveals that the net positive charge of the ammonium
nitrogen irradiates on the neighboring atoms of the amminosugar moiety.    
To a lesser extend, ester carbonyls from PBCA interact with hydroxyl groups from the
amino sugar. 
Another stabilizing factor likely to account for this aggregation property originates from
hydrophobic forces that are developed between the naphtoquinone tricyclic system of
doxorubicin and the carbon-carbon backbone and the butyl ester side-chain of PBCA.  
It can be concluded that oligomeric PBCA’s which are highly lipophilic entities scavenge
amphiphilic doxorubicin already during the polymerization process by extraction of the
protonated species from the aqueous environment to an increasingly lipophilic phase
embodied by the growing PBCA’s. Noteworthy is the establishment of hydrogen bonds
between the ammonium N¾H function and the cyano groups.  
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5.3 Chemotherapy studies
5.3.1 Influence of surfactants on the survival times of glioblastoma-bearing rats
So far, only surface-modified nanoparticles have been shown to mediate a profound brain
delivery.  In the above mentioned study of Steiniger et al. (2004), the most prominent effect
in the brain tumour model was achieved in the group treated with DOX-NP+PS 80. Other
DOX formulations, such as drug solutions in saline or in 1% PS 80 and DOX-loaded in the
uncoated   PBCA   nanoparticles,   were   considerably  less   effective   although   they  also
significantly increased the survival time.  The higher efficacy of DOX-NP+PS 80 was
explained by the ability of this formulation to deliver DOX across the BBB still intact at an
early stage of tumour development due to specific mechanisms activated by the PS 80-
coating of the NP (Kreuter et al. 2003).  It also was assumed that other formulations could
passively diffuse across the leaky endothelium to the tumour. Indeed, as shown by
experiments using Evans Blue as a marker, the permeability of the BBB at the tumour site
on days 5 and 8 is significantly increased (Ambruosi et al., J. Drug Target., submitted).
However, the importance of this passive transport still is not fully elucidated. 
It is well known that tumour uptake due to the EPR effect is more pronounced for the long-
circulating carriers (Moghimi et al. 2001).  The common approach to increase blood half-
life of the particles is shielding of their surface and, consequently, a reduction of
opsonization that can easily be achieved by coating the nanoparticles with surfactants, such
as   poloxamers   or   poloxamines   (block   copolymers   of   polyoxyethylene   and
polyoxypropylene).  Indeed, in a number of studies, the enhanced brain delivery of the drug
bound to the long-circulating  nanoparticles correlated with the increased plasma AUC
(Chen et al. 2001, Zara et al. 2002). 
In the present study, the role of passive drug transport across the leaky BBB to the brain
tumour using PBCA NP coated with two surfactants, poloxamer 188 and poloxamine 908,
that have been extensively used for surface modification of the particulate carriers
(Moghimi and Hunter 2000) was investigated.
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Our results demonstrate that both surfactants considerably increased the anti-tumour effect
of DOX-PBCA: long-term remission was achieved in 20 % (4/20) of animals.  This result
is statistically significant considering that a large number of animals was used in these
experiments. The anti-tumoural effect of the surfactant-coated formulations possibly is
attributable   to   the   EPR   effect.   Indeed,   poloxamine   908-coated  poly(hexadecyl
cyanoacrylate) nanoparticles failed to deliver these particles to the healthy brain (Calvo et
al 2001).  In a parallel manner, the results obtained by Kreuter et al. (1997) demonstrated
that loading of the peptide dalargin to PBCA NP coated with poloxamer 188 did not enable
a delivery of this drug across the intact BBB, whereas dalargin bound to PS 80-coated NP
had a pronounced anti-nociceptive effect in mice, indicating that in the latter case dalargin
was transported across the BBB.  These observations taken together suggest that both,
poloxamer 188 and poloxamine 908 were unlikely to provide transport of the drug-loaded
nanoparticles across the BBB as a result of specific mechanisms but their long-circulating
properties could facilitate the extravasation of nanoparticles across the BBB at the tumour
site. 
At the same time, the higher efficacy of the polysorbate 80-coated nanoparticles may be
explained by the ability of these carriers to deliver the drug across the intact BBB at an
early stage of tumour development due to the receptor-mediated mechanism.  In this way,
doxorubicin also may reach those parts of the brain, which although affected by the
tumour, are still protected by an intact BBB. This result is remarkable since microvascular
permeability in gliomas is heterogeneous and in some parts of the tumour the barrier
function is retained.  The efficacy of DOX-NP+PS 80 most likely cannot be attributed to
the permeabilizing action of PS 80, since DOX solution administered with an equal dose of
PS 80 was less effective (Steiniger et al 2004). 
5.3.2 Influence of formulation variables on the survival times of glioblastoma-bearing
rats
The variation of the ratio between monomer and stabilizer concentration had an  effect on
the particles size but did not influence significantly the drug loading. In particular the mean
particle size was influenced by the concentration of dextran but not by the concentration of
BCA.  This results are in accordance with the study of Alonso et al. (1990). They showed a
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decrease of particle size with increasing dextran concentration. This effect is explicable in
terms of the particle formation process (Douglas et al.1995) as was previously explained
(paragraph 5.1.1.1). Dextran forms a stabilizing layer around the developing nanoparticles.
By increasing the concentration of dextran the formation of the layer is completed earlier,
i.e. reduces the final particle size.
    
Relevant was the influence of pH on particle size and on drug loading (paragraph 5.1.1.3).
Values of a pH larger than 2 led to a rapid polymerization process and the production of an
amorphous polymer mass.  However if the pH was too low the polymerization period was
greatly extended and nanoparticles in this system become swollen with monomer (Douglas
et al. 1985).  In both cases, the particles obtained were not applicable in practice.
      
Nevertheless, the results of the present study showed that the modifications of the variables
only led to subtle variation of drug loading.  Despite those results, preparations 9 and 10
were selected to evaluate their efficacy in the treatment of glioblastoma.
In the reference preparation 0, the addition of DOX occurred 30 min after the beginning of
polymerization to avoid the hydrolytic degradation of doxorubicin in acidic medium
(Beijnen et al 1985).  
In preparation 10, DOX was added before the start of polymerization process.  Despite the
prolonged presence of doxorubicin in the acidic medium, the HPLC assay did not reveal
the presence of any by-products (data not shown).  The addition of doxorubicin before the
beginning of polymerization enormously would simplify the process of nanoparticles
production.  However, the percentage of surviving animals after the treatment with the
formulation  10 in the present study was not satisfactory.  A possible explanation for the
modest efficacy of this preparation may be the increased  content in dextran (2 % w/v).
The molecules of dextran protrude from the surface of nanoparticles as loops or chains
conferring to the particles surface hydrophilic properties (Lemarchand et al. 2004).  The
excess of dextran molecules on the surface most probably produced an effect very similar
to that of the surfactants and, at the same time, interfered with the effective coating of the
particles   with   polysorbate   80.   Consequently,   the   process   of   endocytosis   from   the
endothelial cells of BBB is diminished as well as the transport of doxorubicin into the
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brain. 
Regarding the iso-butyl NP, previous study showed that this polymer presented a reduced
toxicity in comparison with n-butyl NP.  Kante et al.  (1982) demonstrated that the
cumulative mortality of mice after intravenous administration of NP was significant higher
for the latter formulation. Nevertheless, the result of the present study showed that the
efficacy of n-PBCA NP in the treatment of glioblastoma was more pronounced than iso-
PBCA NP. It may be possible that the two polymers present different behaviors in vivo
which requires further investigations.    
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5.4 Body distribution  of polysorbate 80 and doxorubicin-loaded  [
14C]poly
(butyl cyanoacrylate) nanoparticles  after i.v. administration in healthy rats
The results of our experiments showed that no major alterations in body distribution
appeared between the three preparations investigated in the present study,  
14C-PBCA
nanoparticles, 
14C-PBCA nanoparticles overcoated with polysorbate-80, and doxorubicin-
loaded 
14C-PBCA nanoparticles overcoated with polysorbate-80, 30 min before injection
(Figs. 4.7 and 4.8).   The highest concentration of all nanoparticles preparations were
observed in the organs of the reticulo endothelial system (RES), and they were reduced
after polysorbate 80-coating, confirming earlier results with similar particles (Gipps et al.
1986, Gipps et al. 1988, Tröster et al. 1990). Binding of doxorubicin to the nanoparticles,
however, counteracted the polysorbate-coating. 
In contrast, polysorbate 80 almost doubled the concentrations in the brain after 1 hour, but
again this effect was counteracted by the doxorubicin-loading (Fig. 4.6).  This pattern also
was  observable  after  longer time  points.   The delay  in the increase of the brain
concentrations with the two polysorbate-coated nanoparticle preparations is typical for a
delivery mediated by polysorbate 80-coating (Alyautin et al. 1995, Kreuter et al. 1995,
Alyautin et al. 1997,  Gulayev et al. 1999) and may be a reflection of the time-consuming
process of endocytosis.
In order to investigate the reason for this counteractive effect of doxorubicin, the zeta-
potential of the nanoparticles was measured (Table 4.II).  The binding of doxorubicin led to
the alteration of the surface charge towards positive values.  
Although polysorbate 80-overcoating reduced the zeta-potential, a positive net charge
remained.  If the zeta-potential values were measured after incubation in serum, the charges
became negative, and the charge differences diminished, which is a strong indication of an
interaction with serum components (Kreuter 1983d). This interaction in turn has a major
influence on the body distribution (Tröster et al. 1990, Borchard and Kreuter 1993).
The positive charge due to the DOX on the nanoparticles surface can be attributed to the
daunosamine sugar moieties (Brigger et al. 2004).  Brigger et al.  observed a similar effect
caused by doxorubicin loading on the modification of the surface charge as well as the
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body distribution of PEG-coated poly(hexaldecyl cyanoacrylate) nanoparticles.   In their
paper they attributed the alteration of the body distribution to an increase in effective
particle size due to particle aggregation caused by the negatively charged plasma proteins.
However, with our particles we did not observe a significant increase in particle size (Table
4.II) and therefore rather assume that the alteration is caused by a change-induced
difference in cell interaction.  In accordance with the positive-inside rule (von Heijne and
Gavel 1988, von Heijne 1992), the surfaces of cell membranes exhibit a negative
electrostatic charge.  This negative charge is created by a prevalence of negative amino
acids on the outside of membrane proteins. Therefore, it can be assumed that the
electrostatic interactions between the positive DOX-loaded particles and the negative
charged cells and tissues were responsible for the differences in the body distribution of
polysorbate 80-overcoated nanoparticles with and without DOX as well as for the
increased accumulations of the DOX particles in organs of the RES.
It is surprising that coating of the nanoparticles with polysorbate 80 is not increasing their
concentration in the brain to a larger extent and that, moreover,   doxorubicin-loading
reduced this effect rather importantly, although very significant pharmacological effects
(Alyautin et al. 1995, 1997) and higher doxorubicin concentrations (Gulayev et al. 1999) as
well as significant anti-tumoural effects (Steiniger et al. 2004) were obtained with these
preparations.   Alyautdin et al. (2001) already observed that polysorbate 80-coating also
only doubled the concentration of 
3H-dalargin in the brain while a strong non-nociceptive
effect was obtained after this coating and no effect without this coating (Kreuter et al.
1995). In all of these studies that are mentioned above, the total brain concentration was
measured.   It is possible that although this total brain concentration was only slightly
increased by the polysorbate 80-coating, the endocytotic uptake into the brain endothelial
cells that account for only 1 % of the brain mass (Pardridge 1991) nevertheless was
significantly increased. 
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5.5 Biodistribution of polysorbate 80-coated doxorubicin-loaded [
14C]-poly
(butyl cyanoacrylate) nanoparticles after intravenous administration to
glioblastoma-bearing rats
   
The results of the present studies indicate different patterns of biodistribution for the three
formulation investigated, [
14C]-PBCA NP, [
14C]-PBCA NP overcoated with PS 80 , and
DOX-loaded [
14C]-PBCA NP overcoated with PS 80 in tumour bearing rats (Tables 4.V –
4.XI). The results of the body distribution were in accordance with the experiments
performed in healthy rats at all tumour stages. Uncoated nanoparticles accumulated in RES
organs, such as lung, liver, and spleen. Coating of nanoparticles with PS 80 moderately
reduced their uptake in liver and spleen, whereas lung uptake was increased. The influence
of surfactant coating on plasma concentrations was not considerable. These observations
are in accordance with the results of Tröster et al.  (1990) and Araujo et al.  (1999)
demonstrating that the alteration of the nanoparticle surface properties due to the surfactant
leads to an interaction with different opsonins which in turn facilitates the uptake of the
particles by different phagocytosing cells.
In contrast, the uptake of PS 80-coated nanoparticles loaded with DOX was similar to that
of uncoated particles. In fact, the presence of doxorubicin even led to a slight increase of
RES uptake, thus counteracting the polysorbate coating. Similar results were obtained in
the healthy rats (5.4). We observed a comparable counteractive effect of DOX against PS
80 coating.   The different patterns of nanoparticles distribution may, therefore, be
explained by their different physicochemical parameters. Indeed, the measurement of zeta-
potential of nanoparticles resuspended in water and nanoparticles incubated in rat plasma
demonstrated that while unloaded nanoparticles were negatively charged (- 14 mV), the
charge switched to positive after doxorubicin - binding. After the incubation in serum, the
charge of DOX loaded NP became again negative indicating a strong interaction with
serum components. Similar observations were made by Brigger et al. (2004). Thus, the
surface charge present on the nanoparticles plays an important role in proteins interaction,
which, in turn, influences the body distribution (Borchard and Kreuter 1993). The
similarity of body distribution of the [
14C]-nanoparticles in this study performed in tumour-
bearing rats and healthy rats suggests that the pathology associated with the brain tumour
does not influence the physiology of the whole body, possibly due to the limited mass of
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the rat brain (1 % of body weight).
 
Noteworthy is the accumulation of nanoparticles in RES organs and, in particular, of DOX-
loaded NP in lungs 24 h after injection. This phenomenon is explicable considering the
particle redistribution over a period of time.
Figure 4.15 shows the concentration of nanoparticles in the contralatereal hemisphere and
glioblastoma   in   tumour-bearing   rats   10   days   post   tumour   implantation.   These
concentrations were significantly higher in comparison with both, NP brain concentration
in healthy rats (Fig 4.6) and with NP brain concentration in 5 and 8 days tumour-bearing
rats (Figs 4.9, 4.11, 4.13).  In the presence of glioblastoma, the transport of NP into the
brain is the consequence of several factors. In addition to the ability of PS 80 nanoparticles
to cross the BBB which is still intact at an early stage of tumour development, these
carriers can extravasate across the leaky endothelium to the tumour due to the EPR effect
(Maeda et al. 1989, Maeda 2001). 
Indeed,  as  shown   by  extravasation   after   intravenous   injection   of   Evans   Blue,  the
permeability of the BBB at the tumour site on days 5 and 8 was significantly increased
(Fig. 4.16), which provides a basis for the EPR-mediated drug delivery. 
These   observations   are   important   since   microvascular   permeability   in   gliomas   is
heterogeneous (Neuwelt 2004) and whereas in some parts of the tumour, capillaries are
hyper-permeable, in other parts the barrier function may be retained. Thus, in the case of
brain tumours, the ability of  PS 80-coated nanoparticles to deliver drugs across the intact
BBB due to receptor-mediated transcytotic mechanisms is also augmented by their
enhanced ability to accumulate in tumours due to the EPR effect. 
Interestingly, the concentration of PS 80 [
14C]-PBCA NP in glioblastoma was found to be
significantly higher in comparison to DOX [
14C]-PBCA NP concentration.  Brigger et al.
(2004) observed a similar effect for DOX PEG–coated poly(hexaldecyl cyanoacrylate)
nanospheres. In their study of the body distribution in 9L gliosarcoma-bearing rats, DOX-
loaded nanospheres accumulated to a 2.5 fold lesser extent in the tumour as compared to
the unloaded nanospheres.
This phenomenon can be explained considering the microenvironment of cerebral intra-
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tumoural tissue which is different from that in normal brain tissue (Shaller 2004). Regions
within   brain   tumour   are   transiently   or   chronically   hypoxic   (Zagzag   et   al.   2003).
Consequently, the glycolytic metabolism of glucose in hypoxic conditions generates
lactate. Because of the accumulation of lactic acid, a physiological hallmark of hypoxia in
tumour is an increased acidosis. The intra-tumoural acidity that may extend to the peri-
tumoural tissue may have a consequence for the delivery of the charged nanoparticles into
the brain. In particular, the positive charge of the tumour area due to the excess of H
+ may
interfere with the penetration of the positive charged DOX 
14C-PBCA NP. 
Nevertheless, the theoretical amount of doxorubicin bound to nanoparticles and delivered
into the brain is significant higher in the glioblastoma than in the contralateral hemisphere
of tumour-bearing rats and in the brain of healthy rats (Table 5.1). 
Healthy rats Tumour-bearing rats
Brain Controlateral
hemisphere Glioblastoma
[DOX] 0.50 mg 1.06 mg 1.14 mg
Table 5.I. Brain concentration of doxorubicin (mg/g tissue)  at 1 h after intravenous injection into rats of 20
mg/kg of DOX 
14C-PBCA nanoparticles. 
The concentration achieved appears to be adequate to obtain a therapeutic effect in the
treatment of glioblastomas (Steiniger et al. 2004).
5.6 Radioluminography studies
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The results of the radioluminography studies  demonstrated (paragraph 4.5) the variation of
the pattern of  body distribution in rats after i.v. administration of polysorbate 80-coated
14C-DOX   NP   in   accordance   with   the   study  of   the   body  distribution   using  liquid
scintillation. Indeed, polysorbate 80 conferred to the particle surface hydrophilic properties
which permitted a relative avoidance of the RES uptake.
Regarding the brain distribution, the results showed a significant accumulation of the
particles in the liquor and in the pineal body, whereas no detectable activity in the brain
was observed. These results are surprising and, moreover, are not in accordance with the
studies of body distribution using liquid scintillation in which a significant transport of the
labelled particle  into  the brain  was  shown.  It may be argued  that  the high  drug
concentrations in the brain homogenisate observed with the nanoparticles were due to the
particles remaining in the brain blood vessel lumen or the surrounding endothelial cells.
Already Gulayev et al. (1999) explained the inconsistence of this argument considering the
capillary blood volume which represents only 1 % of the total brain volume, and the
endothelial cell volume which is 0.1 %. He found the concentration of 6  mg/g of
doxorubicin in brain homogenisate. If the particles containing drug had remained in the
blood   capillaries,   the   concentration   would   have   been   extremely  high   (6000  mg/g)
considering the exclusive uptake by endothelial cells without release into the residual
brain. These concentration are unreasonably high and would have led to immediate severe
local toxicity which was not observed. Moreover, these concentrations would have shown
up in the autoradiographies. For this reason the total brain concentration of about 1 % of
the dose in the homogenates has to be attributed to the high liquor and pineal body
concentrations.
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6 Conclusions 
Chemotherapeutical  studies  performed  on  glioblastoma–bearing  rats   provide  another
evidence of the considerable anti-tumour effect of doxorubicin loaded in polysorbate 80-
coated PBCA NP in brain tumours. 
Additionally, the results obtained in this study suggest that the mechanism of drug delivery
to the brain tumour depends on the surfactant used for nanoparticle modification.
Therefore, both the long-circulation characteristics and the cell/particle interactions must
be considered in the design of an adequate carrier capable of delivering a drug across the
BBB.
Altogether, these results  suggest that the surface-modified poly(butyl cyanoacrylate)
nanoparticles offer new opportunities for non-invasive chemotherapy of brain tumours.
The studies of body distribution performed in healthy rats and glioblastoma - bearing rats
demonstrated that overcoating of poly(butyl-2-cyano[3-
14C]acrylate) nanoparticles with
polysorbate 80 decreased their concentration in the  organs of the reticuloendothelial
system, i.e. liver, spleen, and lungs. The loading with doxorubicin counteracts the effects of
polysorbate 80-coating. This counteraction by doxorubicin appears to be caused by its
positive charge, which alters the interaction with the plasma components and with other
cells in the body. 
The similarity of the results for tumour-bearing rats and healthy rats suggests that the
pathology associated with the brain tumour does not influence the physiology of the whole
body.
 The accumulation of poly(butyl-2-cyano[3-
14C]acrylate) nanoparticles in the tumour site
and in the contralateral hemisphere in glioblastoma beating-rats demonstrates the efficacy
of the EPR effect on the nanoparticles delivery into the brain.  Although the adsorption of
doxorubicin on nanoparticles surface counteracts the ability of polysorbate 80 to enhance
the transport of nanoparticles into the brain, the actual concentration of doxorubicin
delivered to the tumour site is higher than in the contralateral hemisphere of tumour-
bearing rats and than in the brain of healthy rats. Hence, doxorubicin loaded poly(butyl-2-
cyano[3-
14C]acrylate) nanoparticles have a high potential for the treatment of glioblastoma.
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7 Summary
Introduction
Systemically administered chemotherapy is often ineffective in the treatment of   CNS
diseases.  One reason for this low efficacy is insufficient drug delivery to the brain due to
the presence of the blood-brain barrier (BBB), which restricts exchange of solutes between
the blood and brain extracellular fluid.  The BBB is formed by the endothelial cells of brain
vessels, which, in contrast to peripheral endothelia, are joined by tight junctions.  While
this structural barrier hampers penetration of hydrophilic substances into the brain by
aqueous paracellular diffusional pathways, accumulation of lipophilic molecules in the
brain is often restricted due to the very efficient ABC efflux transporters, such as P-gp or
multidrug resistance proteins (MRP).
One of  the evolving strategies for non-invasive  drug delivery  to the  brain  is the
employment   of   nanoparticle   technology.   Indeed,   as   shown   by   the   extensive
pharmacological studies, poly(butyl cyanoacrylate) nanoparticles coated with polysorbate
80 (Tween
® 80) enabled the brain delivery of a number of drugs that are normally unable to
cross the BBB. It was also demonstrated that the effect of the polysorbate-coating was
unique and other surfactants including poloxamers 188, 338, and 407, and poloxamine 908
could not enable drug delivery into the brain of healthy animals  using poly(butyl
cyanoacrylate) nanoparticles. This phenomenon was explained by the selective adsorption
of certain plasma proteins (in particular, apolipoproteins E and B) on the surface of
nanoparticles coated with polysorbate 80. In this way, the coated polymeric particles
mimicked the lipoprotein particles and were transported across the BBB by receptor-
mediated endocytosis.
However, in the case of brain tumours, when the BBB may be partially disrupted and its
permeability at the tumour site is increased, the nanoparticles might additionally target the
tumour by the enhance permeability and retention (EPR) effect. It is known that the EPR
effect is especially pronounced for the long-circulating nanoparticles that avoid rapid
clearance from the circulation and uptake by the mononuclear phagocyte system (MPS),
which enhances their extravasation in non-MPS tissues.
In the first part of the present study, nanoparticle loading was optimized by altering
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formulation parameters with the objective to develop a formulation with higher efficacy for
the therapy of glioblastoma-bearing rats. Moreover, the potential of doxorubicin bound to
poly(butyl cyanoacrylate) nanoparticles (DOX – PBCA NP) coated with stealth agents for
the chemotherapy of brain tumours was investigated.  
In the second part of this study the brain distribution and the body distribution in healthy
rats and in glioblastoma 101/8-bearing rats after i.v. administration of poly(butyl-2-cyano
[3-
14C]acrylate) nanoparticles coated with polysorbate 80 and loaded with doxorubicin
(DOX - 
14C PBCA + PS 80) was investigated.
Antitumour effect of doxorubicin loaded in poly(butyl cyanoacrylate) nanoparticles
in rat glioma model: influence of formulation parameters 
The standard formulation of DOX – PBCA NP used in this study was prepared by anionic
polymerization of butyl cyanoacrylate (BCA) in presence of DOX. The measurement of the
drug loading was performed by HPLC and by spectrophotometer. The drug loading of the
standard formulation measured by HPLC was 71 %. Different formulation of DOX-PBCA
NP were made by changing the parameters of the normal procedure. Changed parameters
were: pH, concentration and type of monomer, concentration and type of steric stabilizator,
polymerization time and addition of the drug at beginning of polymerization process. The
employment of iso-BCA instead of n-BCA allowed the attainment of nanoparticles with
improved loading (73 % of drug loading by HPLC) compared to the standard formulation.
A new formulation with improved loading also was obtained by reduction of n-BCA
concentration (0.75 % w/v), combined with an increase of dextran concentration (2 % w/v),
prolongation of polymerization time to 4 h, and addition of doxorubicin before the start of
the polymerization (76 % of drug loading by HPLC). 
The therapeutic potential for the treatment of glioblastoma of the following formulations
was   tested:   1)   doxorubicin   in   saline   (DOX);   2)   standard  formulation   coated   with
polysorbate   80;   3)   standard   formulation   coated   with   poloxamine   908;   4)   standard
formulation coated with poloxamer 188; 5) new formulation coated with polysorbate 80; 6)
iso-PBCA nanoparticles coated with polysorbate 80. Untreated animals were used as a
control. These preparations were injected i.v. into the tail vein using the dose regimen of 3
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x 1.5 mg/kg on days 2, 5, and 8 post tumor implantation. The concentration of doxorubicin
in the injection solution was 0.25 %.
 
The results of the present study showed  that the standard formulation coated with
polysorbate 80 (PS 80) was the most effective: 35 % of the animals treated with this
formulation survived for 180 days after tumour implantation. In the group treated with PS
80-coated iso-PBCA nanoparticles the percentage of long-term survivors was 15 % (3/20)
whereas the percentage of survivers in the group treated with the new formulation coated
with PS 80 was 10 % (2/20). The percentage of long-term survivors treated with DOX-
PBCA NP coated with poloxamer 188 or poloxamine 908 was 20 % (4/20). Free DOX in
solution was less effective: 10 % animals (2/20) survived for 65 days. All control animals
died between day 18 and day 24.
The higher efficacy of DOX-PBCA NP coated with PS 80 may be explained by the ability
of these carriers to deliver the drug across the intact BBB at an early stage of tumour
development due to the receptor-mediated mechanism activated by the PS 80-coating of
the NP. In this way, doxorubicin also may reach those parts of the brain, which though
affected by the tumour, are still protected by an intact BBB.
Our results demonstrate also that poloxamer 188 and poloxamine 908 considerably
increased the anti - tumour effect of DOX-PBCA NP although earlier studies showed that
the coating with these surfactants failed to deliver drugs to the healthy brain. The anti -
tumoural effect of the surfactant-coated formulations possibly is attributable to the EPR
effect. It is well known that tumour uptake due to the EPR effect is more pronounced for
long-circulating carriers.  The common approach to increase blood half-life of the particles
is shielding of their surface and, consequently, a reduction of opsonization that can be
achieved   by   coating   the   nanoparticles   with   surfactants,   such   as   poloxamers   or
poloxamines. Although poloxamer 188 and poloxamine 908 were unlikely to provide
transport of the drug-loaded  nanoparticles across the BBB they could still facilitate their
extravasation across the BBB at the tumour site. 
The percentage of surviving animals after the treatment with the new formulation with
increased loading in the present study was not satisfactory.  A possible explanation for the
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modest efficacy of this preparation may be the increased content in dextran (2 % w/v). The
molecules of dextran protrude from the surface of nanoparticles as loops or chains
conferring to the particles surface hydrophilic properties which could interfere with the
effective coating by polysorbate 80. Consequently, the process of endocytosis by the
endothelial cells of BBB may be diminished  as well as the transport of doxorubicin into
the brain. Regarding the iso-PBCA NP, it may be possible that the two polymers behave
differently in vivo which requires further investigations.
Body distribution in healthy rats and in glioblastoma 101/8-bearing rats of DOX - 
14C
PBCA nanoparticles
Uncoated   nanoparticles,   polysorbate   80-coated   nanoparticles,   or   doxorubicin   loaded
nanoparticles were injected into the tail veins of healthy rats. After different time points (10
min, 1 h, 6 h, 24 h, 1 week, 4 weeks), the animals were sacrificed by placing in carbon
dioxide and subsequent decapitation. Blood was collected and liver, spleen, lungs, kidneys,
gonads, and the brain were removed. Aliquots of organs were digested in tissue solubilizer
and the radioactivity was measured by scintillation counting. The same procedure was
employed for tumour-bearing rats. Nanoparticle administration was performed on days 5, 8
and 10 after tumour inoculation, and rats were sacrificed at the following time points: 10
min, 1 h, 6 h, and 24 h. Blood and organs were collected and the radioactivity was
determined. The pattern of body distribution of the [
14C]-nanoparticles was similar in both
tumour-bearing rats and healthy rats. This result suggests that the pathology associated
with the brain tumour does not influence the physiology of the whole body. The three
formulation investigated, [
14C]-PBCA NP, [
14C]-PBCA NP coated with PS 80 , and DOX-
loaded [
14C]-PBCA NP coated with PS 80 showed different patterns of biodistribution. As
expected, uncoated nanoparticles accumulated in RES organs, such as lungs, liver, and
spleen. Coating of nanoparticles with PS 80 moderately reduced their uptake in liver and
spleen, whereas lung uptake was increased. These observations demonstrate that the
alteration of the nanoparticle surface properties due to the surfactant led to an interaction
with different opsonins, which in turn facilitated the uptake of the particles by different
phagocytosing cells. In contrast, the uptake of PS 80-coated nanoparticles loaded with
DOX was similar to that of uncoated particles. In fact, the presence of doxorubicin even led
to a slight increase of RES uptake, thus counteracting the polysorbate coating. The
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different   patterns   of  nanoparticles   distribution  may  be   explained  by  their   different
physicochemical   parameters.   Indeed,   the   measurement   of   the   zeta-potential   of
nanoparticles resuspended in water and of nanoparticles incubated in rat plasma showed
that unloaded nanoparticles were negatively charged, whereas the charge switched to
positive after doxorubicin binding. After the incubation in serum, the charge of DOX-
loaded NP became again negative indicating a strong interaction with serum components.
Thus, the surface charge present on the nanoparticles plays an important role in protein
interaction, which, in  turn, influences the body distribution. 
 
Regarding the brain distribution, the concentration of nanoparticles in tumour-bearing rats
10 days post tumour implantation was significantly higher in comparison with NP
concentrations in healthy rats and NP concentration in 5 and 8 days tumour-bearing rats. In
the presence of glioblastomas, the transport of NP into the brain is a consequence of
several factors: in addition to the ability of PS 80 nanoparticles to cross the BBB which is
still intact at an early stage of tumour development, these carriers can extravasate across
the leaky endothelium to the tumour due to the EPR effect.  These observations are
important since microvascular permeability in gliomas is heterogeneous, and whereas in
some parts of the tumour the capillaries are hyper-permeable, in other parts the barrier
function may be retained. Thus, in the case of brain tumours, the ability of PS 80-coated
nanoparticles to deliver drugs across the intact BBB due to receptor-mediated transcytotic
mechanisms also is augmented by their enhanced ability to accumulate in tumours due to
the EPR effect. 
Interestingly, the concentration of PS 80 [
14C]-PBCA NP in glioblastoma was found to be
significantly   higher   in   comparison   to   DOX   [
14C]-PBCA   NP   concentration.   This
phenomenon  can be  explained considering  the  microenvironment  of  cerebral  intra-
tumoural tissue which is different from that in normal brain tissue. Regions within brain
tumours are transiently or chronically hypoxic. A physiological hallmark of hypoxia in
tumours is an increased acidosis. The intra-tumoural acidity that may extend to the peri-
tumoural tissue may have consequences for the delivery of the charged nanoparticles into
the brain. In particular, the positive charge of the tumour area due to the excess of H
+ may
interfere with the penetration of the positive charged DOX 
14C-PBCA NP. Nevertheless,
the doxorubicin concentrations achieved in the glioblastomas appear to be adequate to
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obtain a therapeutic effect in the treatment of glioblastomas. 
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